Compugen (CGEN) 20-F 12 Mar 15 2014 FY Annual report (foreign) Financial data

Document_and_Entity_Informatio

Document and Entity Information	12 Months Ended
	Dec. 31, 2014
Document and Entity Information [Abstract]
Document Type	20-F
Amendment Flag	FALSE
Document Period End Date	31-Dec-14
Entity Registrant Name	COMPUGEN LTD
Entity Central Index Key	1119774
Current Fiscal Year End Date	-19
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2014
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding	50,254,492
Entity Current Reporting Status	Yes
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
CURRENT ASSETS:
Cash and cash equivalents	$25,643	$28,751
Restricted cash	543	154
Short-term bank deposits	47,000	18,015
Investment in Evogene	1,054	4,565
Other accounts receivable and prepaid expenses	858	1,731
Total current assets	75,098	53,216
NON-CURRENT ASSETS:
Long-term bank deposits	35,026
Long-term prepaid expenses	108	158
Severance pay fund	2,024	2,129
Property and equipment, net	2,730	1,208
Total non-current assets	39,888	3,495
Total assets	114,986	56,711
CURRENT LIABILITIES:
Trade payables	1,493	693
Deferred revenue	1,789	5,318
Research and development funding arrangement	421
Other accounts payable and accrued expenses	2,886	1,728
Total current liabilities	6,589	7,739
NON-CURRENT LIABILITIES:
Research and development funding arrangement		13,189
Deferred revenue		1,454
Accrued severance pay	2,281	2,441
Total non-current liabilities	2,281	17,084
COMMITMENTS AND CONTINGENT LIABILITIES
SHAREHOLDERS' EQUITY:
Share capital: Ordinary shares of NIS 0.01 par value: 100,000,000 shares authorized at December 31, 2014 and 2013; 50,254,492 and 41,002,113 shares issued and outstanding at December 31, 2014 and 2013, respectively	137	111
Additional paid-in capital	324,053	235,351
Accumulated other comprehensive income	1,222	4,628
Accumulated deficit	-219,296	-208,202
Total shareholders' equity	106,116	31,888
Total liabilities and shareholders' equity	$114,986	$56,711

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) (ILS)	Dec. 31, 2014	Dec. 31, 2013
CONSOLIDATED BALANCE SHEETS [Abstract]
Ordinary shares, par value per share	0.01	0.01
Ordinary shares, shares authorized	100,000,000	100,000,000
Ordinary shares, shares issued	50,254,492	41,002,113
Ordinary shares, shares outstanding	50,254,492	41,002,113

CONSOLIDATED_STATEMENTS_OF_COM

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS [Abstract]
Revenue	$12,367	$3,549	$242
Cost of revenue	3,344	2,509	201
Gross profit	9,023	1,040	41
Operating expenses:
Research and development expenses, net	15,074	12,275	9,442
Marketing and business development expenses	838	962	684
General and administrative expenses	5,448	4,846	3,457
Total operating expenses	21,360	18,083	13,583
Operating loss	-12,337	-17,043	-13,542
Financial income (loss), net	1,758	3,460	-86
Equity loss	-155
Loss before tax expenses	-10,734	-13,583	-13,628
Income taxes	-360	-500
Net loss	-11,094	-14,083	-13,628
Basic net loss per share	($0.23)	($0.36)	($0.38)
Diluted net loss per share	($0.26)	($0.36)	($0.38)
Other comprehensive loss:
Unrealized gain (loss) arising during the period on the investment in Evogene	-1,202	2,972	1,103
Realized gain arising during the period on the investment in Evogene	-2,345	-3,711
Unrealized gain arising during the period from foreign currency derivative contracts	141
Total comprehensive loss	($14,500)	($14,822)	($12,525)
Weighted average number of ordinary shares used in computing basic net loss per share	47,808,855	38,869,438	35,844,496
Weighted average number of ordinary shares used in computing diluted net loss per share	48,387,063	38,869,438	36,249,262

STATEMENTS_OF_CHANGES_IN_SHARE

STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (USD $)	Total	Ordinary shares [Member]	Additional paid-in capital [Member]	Accumulated other comprehensive income [Member]	Accumulated deficit [Member]
In Thousands, except Share data
Balance at Dec. 31, 2011	$19,581	$94	$195,714	$4,264	($180,491)
Balance, shares at Dec. 31, 2011		34,707,622
Options exercised	1,880	2	1,878
Options exercised, shares		696,988
Issuance of shares, net	6,267	3	6,264
Issuance of shares, net, shares		1,185,868
Stock-based compensation relating to options and warrants issued to non-employees	145		145
Stock-based compensation relating to options issued to employees and directors	2,324		2,324
Other comprehensive income (loss) from marketable securities	1,103			1,103
Other comprehensive income from foreign currency derivative contracts
Net loss	-13,628				-13,628
Balance at Dec. 31, 2012	17,672	99	206,325	5,367	-194,119
Balance, shares at Dec. 31, 2012		36,590,478
Options exercised	5,631	5	5,626
Options exercised, shares		1,786,473
Issuance of shares, net	19,704	7	19,697
Issuance of shares, net, shares		2,625,162
Stock-based compensation relating to options and warrants issued to non-employees	164		164
Stock-based compensation relating to options issued to employees and directors	3,379		3,379
Classification of liability with respect to outstanding options to non-employee to equity	160		160
Other comprehensive income (loss) from marketable securities	-739			-739
Other comprehensive income from foreign currency derivative contracts
Net loss	-14,083				-14,083
Balance at Dec. 31, 2013	31,888	111	235,351	4,628	-208,202
Balance, shares at Dec. 31, 2013	41,002,113	41,002,113
Options exercised	1,423	1	1,422
Options exercised, shares		389,289
Issuance of shares, net	70,718	21	70,697
Issuance of shares, net, shares		7,263,090
Issuance of shares in respect to Termination and Equity Conversion Agreement	12,954	4	12,950
Issuance of shares in respect to Termination and Equity Conversion Agreement, shares		1,600,000
Stock-based compensation relating to options and warrants issued to non-employees	361		361
Stock-based compensation relating to options issued to employees and directors	3,272		3,272
Other comprehensive income (loss) from marketable securities	-3,547			-3,547
Other comprehensive income from foreign currency derivative contracts	141			141
Net loss	-11,094				-11,094
Balance at Dec. 31, 2014	$106,116	$137	$324,053	$1,222	($219,296)
Balance, shares at Dec. 31, 2014	50,254,492	50,254,492

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Cash flows from operating activities:
Net loss	($11,094)	($14,083)	($13,628)
Adjustments required to reconcile net loss to net cash used in operating activities:
Stock-based compensation	3,633	3,543	2,469
Depreciation	658	370	299
Severance pay, net	-55	59	75
Gain from sale of Evogene shares	-2,345	-3,711
Change in fair value of exchange option and embedded derivatives within research and development funding arrangements	-269	811	588
Amortization of the Research and Development Component within research and development funding arrangement	-337	-230	-130
Change in the fair value of liability with respect to outstanding options to non-employee		-104	-20
Loss in respect to Termination and Equity Conversion Agreement	792
Decrease (increase) in other accounts receivable and prepaid expenses	1,026	-1,105	-112
Increase (decrease) in deferred revenues	-4,983	6,772
Decrease (increase) in long-term prepaid expenses	152	202	-301
Increase (decrease) in trade payables and other accounts payable and accrued expenses	1,674	1,037	-86
Net cash used in operating activities	-11,148	-6,439	-10,846
Cash flows from investing activities:
Proceeds from maturity of short-term bank deposits	18,015	3,215	16,525
Investment in short-term bank deposits	-47,000	-18,015	-3,215
Investment in long-term bank deposits	-35,026
Changes in restricted cash	-389	-50
Purchase of property and equipment	-1,896	-328	-1,005
Increase in long-term lease deposits	-102		-42
Proceeds from sale of investment in Evogene	2,309	3,603
Net cash provided by (used in) investing activities	-64,089	-11,575	12,263
Cash flows from financing activities:
Proceeds from issuance of ordinary shares, net	70,718	19,760	6,211
Proceeds from research and development funding arrangements		5,000	1,000
Proceeds from exercise of options	1,411	5,631	1,900
Net cash provided by financing activities	72,129	30,391	9,111
Increase (decrease) in cash and cash equivalents	-3,108	12,377	10,528
Cash and cash equivalents at the beginning of the year	28,751	16,374	5,846
Cash and cash equivalents at the end of the year	25,643	28,751	16,374
Supplemental disclosure of non-cash investing and financing activities:
Issuance of shares in respect to Termination and Equity Conversion Agreement	12,162
Receivables from foreign currency derivative contracts	141
Receivables on account of shares	12		56
Purchase of property and equipment	284		47
Cash paid (received) during the year for:
Income taxes	360	500
Interest payments received from bank short-term deposits and cash equivalents	($235)	($112)	($297)

GENERAL

GENERAL	12 Months Ended
	Dec. 31, 2014
GENERAL [Abstract]
GENERAL	NOTE 1:-  GENERAL
		a.	Compugen Ltd. (the "Company") is a leading drug discovery company focused on monoclonal antibodies and therapeutic proteins to address important unmet needs in the fields of oncology and immunology. The Company utilizes  a broad and continuously growing integrated  infrastructure of proprietary scientific understandings and predictive platforms, algorithms, machine learning systems and other computational biology capabilities for the in silico (by computer) prediction and selection of novel drug candidates, which are then advanced in its Pipeline Program. Beginning in late 2010, the Company established the Pipeline Program, consisting of targets and product candidates for applications in oncology and immunology, based largely on novel immune checkpoint regulator candidates discovered by the Company. The Company's business model includes entering into collaborations covering the further development and commercialization of product candidates at various stages from its Pipeline Program and various forms of research and discovery agreements, in both cases providing the Company with potential milestone payments, royalties and other forms of revenue sharing payments.
			The Company's headquarters are located in Israel, the research and development facilities are located both in Israel and through its wholly-owned U.S. subsidiary, Compugen USA, Inc. ("Compugen Inc.") in South San Francisco, California.
		b.	On August 5, 2013, the Company entered into a Research and Development Collaboration and License Agreement ("Bayer Agreement") with Bayer Pharma AG ("Bayer") for the research, development, and commercialization of antibody-based therapeutics for antibody based therapeutics against two novel, Compugen-discovered immune checkpoint regulators.
			Under the terms of the Bayer Agreement, the Company received an upfront payment of $ 10,000, and is eligible to receive an aggregate of over $ 500,000 in potential milestone payments for both programs, not including aggregate preclinical milestone payments of up to $ 30,000 during the research programs. Additionally, the Company is eligible to receive mid to high single digit royalties on global net sales of any approved products under the collaboration.
			Under the Bayer Agreement, the Company and Bayer will jointly pursue a preclinical research program with respect to each of the two immune checkpoint regulators. A joint steering committee consisting of an equal number of representatives from each party will be responsible for overseeing and directing each such research program pursuant to agree upon work-plans. Each party will be responsible for the costs and expenses incurred by it in performing its designated activities under the work-plans during the research programs. Following each such research program, Bayer will have full control over further clinical development of any cancer therapeutic product candidates targeting the Company-discovered immune checkpoint regulators and will have worldwide commercialization rights for any approved products.

SIGNIFICANT_ACCOUNTING_POLICIE

SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2014
SIGNIFICANT ACCOUNTING POLICIES [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	NOTE 2:- SIGNIFICANT ACCOUNTING POLICIES
	The consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States ("U.S. GAAP").
	a.      Use of estimates:
	The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions. The Company's management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
	b.      Financial statements in U.S. dollars:
	The functional currency of the Company is the U.S. dollar, as the Company's management believes that the U.S. dollar is the primary currency of the economic environment in which the Company and Compugen Inc. have operated and expect to continue to operate in the foreseeable future. The majority of the Company's revenues and financing transactions were made in U.S. dollars. The majority of the Company operations are currently conducted in Israel and most of the expenses in Israel are currently paid in new Israeli shekels ("NIS").
	Transactions and balances denominated in U.S. dollars are presented at their original amounts. Monetary accounts denominated in currencies other than the dollar are re-measured into dollars in accordance with ASC No. 830, "Foreign Currency Matters". All transaction gains and losses of the re-measurement of monetary balance sheet items are reflected in the consolidated statement of comprehensive loss as financial income or expenses, as appropriate.
	c.      Basis of consolidation:
	The consolidated financial statements include the accounts of the Company and Compugen Inc., Intercompany transactions and balances have been eliminated upon consolidation.
	d.      Cash equivalents:
	Cash equivalents are short-term highly liquid investments that are readily convertible to cash with original maturities of three months or less at acquisition.
	e.      Restricted cash:
	Restricted cash held in interest bearing saving accounts which are used as a security for the Company's Israeli facilities leasehold bank guarantee, foreign currency derivative contracts, and credit card security for Compugen Inc.
	.
	f.      Short-term bank deposits
	Bank deposits with maturities of more than three months but less than one year are included in short-term bank deposits. Such short-term bank deposits are stated at cost which approximates market values.
	The short-term bank deposits as of December 31, 2014 and 2013 are in U.S. dollar and bear an annual average interest rate of 0.85% and 0.63%, respectively.
	g.      Marketable securities:
	The Company accounts for its investment in Evogene Ltd. ("Evogene") in accordance with ASC No. 320, "Investments - Debt and Equity Securities".
	Management determines the appropriate classification of its investments at the time of purchase and reevaluates such determinations at each balance sheet date.
	The Company classifies its investment in Evogene as available-for-sale securities which are carried at fair value, with the unrealized gains and losses, reported in "accumulated other comprehensive income (loss)" in shareholders' equity. Realized gains and losses on sale of investments are included in "financial income (loss), net" and are derived using the specific identification method for determining the cost of securities.
	The Company recognizes an impairment charge when a decline in the fair value of its investments is below the cost basis of such securities and is judged to be other-than-temporary. Factors considered in making such a determination include the duration and severity of the impairment, the reason for the decline in value, the potential recovery period and the Company's intent to sell, including whether it is more likely than not that the Company will be required to sell the investment before recovery of cost basis. During the years 2014, 2013 and 2012, no impairment losses have been identified.
	As of December 31, 2014 and 2013, the Company holds 113,405 and 232,292 shares representing less than 1% of Evogene outstanding ordinary shares.
	h.      Non-current prepaid expenses:
	Non-current prepaid expenses consist of non-current lease deposits as security for the Compugen Inc.'s facility lease, motor vehicles leases and non-refundable payments for research and developments services (see also Note 8e).
	i.      Long-term bank deposits:
	Bank deposits with maturities of more than one year are included in long-term bank deposits.
	The long-term bank deposits as of December 31, 2014 are in U.S. dollar and bear an annual average interest rate of 1.02% .The long-term bank deposits matures in the period between May-June 2016.
	j.      Property and equipment, net:
	Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following annual rates:
		%
	Computers, software and related equipment	33
	Laboratory equipment and office furniture	6 - 20 (mainly 20)
	Leasehold improvements	Shorter of the term of the lease or useful life
	k.      Impairment of long-lived assets:
	The long-lived assets of the Company and Compugen Inc. are reviewed for impairment in accordance with ASC 360, "Property, Plant, and Equipment", whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset with the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. During the years 2014, 2013 and 2012, no impairment losses have been identified.
	l.      Revenue recognition:
	The Company generates revenue mainly from its Research and Development Collaboration and License Agreement. The revenues are derived mainly from upfront license payments, research and development services and contingent payments related to milestones achievements.
	The Company applies ASC 605-25, "Multiple-Element Arrangements" pursuant to which each required deliverable is evaluated to determine whether it qualifies as a separate unit of accounting based on whether the deliverable has "stand-alone value". The arrangement's consideration that is fixed or determinable is then allocated to each separate unit of accounting based on the relative selling price of each deliverable which is not contingent based on its vendor specific objective evidence (''VSOE'') if available, third party evidence (''TPE'') if VSOE is not available, or estimated selling price (''ESP'') if neither VSOE nor TPE is available.
	Revenues from upfront license payments and research and development services are recognized according to the proportional performance method along the research and development services period in accordance with ASC 605-10, "Revenue Recognition".
	As of December 31, 2014 and 2013 the Company deferred revenues in respect to the upfront license payment amounted to $ 1,789 and $ 6,711, respectively.
	Contingent payments related to milestones achievement and royalties are recognized immediately upon the accomplishment of futures events, in accordance with ASC 605-28, "Revenue Recognition – Milestone Method".
	On June 27, 2014, and October 14, 2014 the Company achieved the first and second substantive milestones with respect to one licensed program, under the Bayer Agreement according to which the Company recognized revenues in total amount of $ 7,200 in accordance with the criteria prescribed under ASC 605-28.
	m.      Cost of revenues:
	Cost of revenues consist mainly of research and development expenses attributed to the Research and Development Collaboration and License Agreement, as well as certain royalties paid.
	n.      Research and development expenses, net:
	Research and development expenses are charged to the statement of comprehensive loss as incurred.
	Royalty and non-royalty bearing grants from the Office of the Chief Scientist of the Israel Ministry of Industry, Trade & Labor ("OCS") and the Bi-national Industrial Research ("BIRD") for funding approved research and development projects, are recognized at the time the Company is entitled to such grants, on the basis of the research and development expenses incurred. Such grants are presented as a reduction from research and development expenses in the consolidated statements of comprehensive loss.
	The Research and Development component, as defined in note 7, is recognized at the time the Company received the payments under research and development funding arrangement, which is calculated as residual between the payments received and the embedded derivatives, and is amortized over the period in which the development is being provided in connection with the relevant designated product candidates. Such component is deducted from research and development expenses in the consolidated statements of comprehensive loss.
	o.      Severance pay:
	The Company's liability for severance pay for its Israeli employees is calculated pursuant to Israeli Severance Pay Law based on the most recent salary of the employees multiplied by the number of years of employment as of the balance sheet date, and is in large part covered by regular deposits with recognized pension funds, deposits with severance pay funds and purchases of insurance policies. The value of these deposits and policies is recorded as an asset in the Company's balance sheet.
	Pursuant to Section 14 of the Israeli Severance Pay Law, for Israeli employees under this section, the Company's contributions for severance pay have replaced its severance obligation. Upon contribution of the full amount of the employee's monthly salary for each year of service, no additional calculations is conducted between the parties regarding the matter of severance pay and no additional payments is made by the Company to the employee. Further, the related obligation and amounts deposited on behalf of the employee for such obligation are not stated on the balance sheet, as the Company is legally released from the obligation to employees once the deposit amounts have been paid.
	Severance expenses for the years ended December 31, 2014, 2013 and 2012 amounted to approximately $ 344, $ 294 and $ 252, respectively.
	p.      Stock-based compensation:
	The Company accounts for stock-based compensation in accordance with ASC 718, "Compensation - Stock Compensation", ("ASC 718"), which requires companies to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company's consolidated statement of comprehensive loss.
	The Company recognizes compensation expenses for the value of its awards granted based on the straight-line method over the requisite service period of each of the awards, net of estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Estimated forfeitures are based on actual historical pre-vesting forfeitures.
	The Company selected the Black-Scholes-Merton ("Black-Scholes") option-pricing model (except as mentioned in Note 9e) as the most appropriate fair value method for the majority of its share-options awards and values share based on the market value of the underlying shares at the date of grant. The option-pricing model requires a number of assumptions, of which the most significant are the expected share price volatility and the expected option term. Expected volatility was calculated based on actual historical share price movements over a term that is equivalent to the expected term of granted options. The expected term of options granted is based on historical experience and represents the period of time that options granted are expected to be outstanding.
	The risk-free interest rate is based on the yield from U.S. treasury bonds with an equivalent term. The Company has historically not paid dividends and has no foreseeable plans to pay dividends.
	The Company used the following weighted-average assumptions for granted options:
				Year ended December 31,
				2014			2013			2012
	Volatility				56	%		71	%	82	%
	Risk-free interest rate				1.53	%		1.25	%	0.66	%
	Dividend yield				0	%		0	%	0	%
Expected life (years)				4.7			4.4		4.5
The Company applies ASC 505-50, "Equity-Based Payments to Non-Employees" ("ASC 505") with respect to options and warrants issued to non-employees which requires the use of option valuation models to measure the fair value of the options and warrants at the measurement date.
q.      Concentration of credit risks:
Financial instruments that potentially subject the Company and Compugen Inc. to concentration of credit risk consist principally of cash and cash equivalents, restricted cash, short-term bank deposits, marketable securities, long-term bank deposits and foreign currency derivative contracts.
Cash, cash equivalents, restricted cash and short-term bank deposits are invested in major banks in Israel and in the U.S. Generally, these deposits may be redeemed upon demand and bear minimal risk.
Long-term bank deposits are invested in major banks in Israel. Management believes that the financial institutions that hold the Company's investment are financially sound and, accordingly, minimal credit risk exists with respect to this investment.
The Company's marketable securities consist of investment in Evogene ordinary shares which are publicly traded in the U.S. and Israel.
r.      Basic and diluted loss per share:
Basic loss per share is calculated based on the weighted average number of ordinary shares outstanding during each year. Diluted net loss per share is calculated based on the weighted average number of ordinary shares outstanding during each year, plus dilutive potential in accordance with ASC 260, "Earnings per Share."
All outstanding share options and warrants for the years ended December 31, 2014, 2013 and 2012 have been excluded from the calculation of the diluted net loss per share because all such securities are anti-dilutive for all periods presented. As of December 31, 2014, 2013 and 2012 the total weighted average number of shares related to outstanding options excluded from the calculations of diluted net loss per share were 6,363,348, 6,271,819 and 6,170,554, respectively. The total weighted average number of shares related to warrants under the research and development funding arrangement excluded from the calculations of diluted net loss per share were 333,333 for the year ended December 31, 2014 and 500,000 for each of the years ended December 31, 2013 and 2012. As of December 31, 2013 the total weighted average number of shares related to the exchange option under the research and development funding arrangement excluded from the calculations of diluted net loss per share was 2,157,293.
s.      Income taxes:
The Company accounts for income taxes in accordance with ASC No. 740, "Income Taxes", ("ASC 740") which prescribes the use of the liability method whereby deferred tax asset and liability account balances are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value. As of December 31, 2014 and 2013, a full valuation allowance was provided by the Company.
ASC 740 contains a two-step approach to recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. As of December 31, 2014 and 2013 no liability for unrecognized tax benefits was recorded as a result of ASC 740.
t.      Fair value of financial instruments:
The Company applies ASC 820, "Fair Value Measurements and Disclosures" ("ASC 820"), pursuant to which fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the "exit price") in an orderly transaction between market participants at the measurement date.
In determining fair value, the Company uses various valuation approaches. ASC 820 establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company.
Unobservable inputs are inputs that reflect the Company's assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances.
The hierarchy is broken down into three levels based on the inputs as follows:
	Level 1 -	Quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company can access at the measurement date.
	Level 2 -	Valuations based on one or more quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.
	Level 3 -	Valuations based on inputs that are unobservable and significant to the overall fair value measurement.
The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.
The carrying amounts of cash and cash equivalents, restricted cash, short-term bank deposits, other accounts receivable, trade payables, and other accounts payable and accrued expenses approximate their fair values due to the short-term maturities of such instruments.
The Company measures its investment in Evogene, embedded derivatives with respect to research and development funding arrangement, the liability with respect to outstanding options to non-employees and foreign currency derivative contracts at fair value (see also Note 11).
u.      Derivative instruments:
The Company accounts for derivatives and hedging based on ASC 815, “Derivatives and Hedging”. ASC 815 requires the Company to recognize all derivatives on the balance sheet at fair value. The accounting for changes in the fair value (i.e., gains or losses) of a derivative instrument depends on whether it has been designated and qualifies as part of a hedging relationship and on the type of hedging relationship. For those derivative instruments that are designated and qualify as hedging instruments, the Company must designate the hedging instrument, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of a net investment in a foreign operation. If the derivatives meet the definition of a hedge and are so designated, depending on the nature of the hedge, changes in the fair value of such derivatives will either be offset against the change in fair value of the hedged assets, liabilities, or firm commitments through earnings, or recognized in other comprehensive income until the hedged item is recognized in earnings. The ineffective portion of a derivative's change in fair value is recognized in earnings.
The Company entered into forward contracts to hedge against the risk of overall changes in future cash flow from payments of payroll and related expenses as well as other expenses denominated in NIS. As of December 31, 2014, the Company had outstanding forward contracts in the notional amount of $ 5,626. These contracts were for a period of nine months ended September 30, 2015. The Company measured the fair value of the contracts in accordance with ASC 820 (classified as level 2).
These contracts met the requirement for cash flow hedge accounting and as such during 2014 unrealized gains in the amount of $ 141 were recognized under other comprehensive income, none of the related expenses were incurred and therefore the Company did not classify any of the amount to operating expenses. The fair value of the Company's outstanding forward contracts at December 31, 2015 amounted to unrealized gains of $ 141.
v.      Investment in affiliates:
The Company accounts for its investment in affiliated companies under the equity method in accordance with ASC 323, "Investments-Equity Method". For the purpose of these financial statements, an affiliated company is a company held to the extent of 20% or more, or a company less than 20% held, in which the Company can exercise significant influence over operating and financial policy of the affiliate.
The Company has two investments in affiliates, Neviah Genomics Ltd. ("Neviah") and Keddem BioScience Ltd. ("Keddem"). The Company does not have control over Neviah and Keddem, however has significant influence through holding rights of 25.12% and 36%, respectively. The Company accounts for its investment in Neviah and Keddem under the equity method. Both Neviah and Keddem are in accumulated loss position until December 31, 2014 and because the Company has no commitment to fund Neviah's and Keddem's operations, no investment account was recorded in the Company's consolidated financial statements as of December 31, 2014 and 2013.
On December 17, 2014 ("Loan Grant Date") the Company, Merck Holdings Netherlands B.V. ("Merck Holdings") and Neviah entered into Convertible Bridge Loan ("Loan") Agreement ("Loan Agreement") in total amount of Euro 500 thousand ("Loan Amount") to finance Neviah's operations. Under the agreement, the Company provided an amount of $ 155 reflecting its respective portion of the Loan Amount. The Loan is granted for a period of 18 months from the Loan Grant Date ("Loan Term") and bear interest at an annual rate of 2%.
The Loan is automatically converted under certain terms in the event of Qualified Investment or M&A Transaction as defined in the Loan Agreement. In addition if a Qualified Investment does not occur within six months from the Loan Grant Date, the Company may elect to convert the Loan under certain terms as defined in the Loan Agreement.
Following the financing of the Loan as described above, the Company recorded equity losses of $ 155 in respect to the total amount provided to Neviah.
w.      Comprehensive income (loss):
The Company accounts for comprehensive income (loss) in accordance with ASC 220, "Comprehensive Income". This statement establishes standards for the reporting and display of comprehensive income (loss) and its components in a full set of general purpose financial statements. Comprehensive income (loss) generally represents all changes in shareholders' equity during the period except those resulting from investments by, or distributions to, shareholders. The Company elected to present the comprehensive income in a single continuous statement. The Company determined that its items of other comprehensive income (loss) relate to unrealized gains on foreign currency derivative contracts and unrealized gains on available- for- sale marketable securities.
x.      New Accounting Pronouncements and Other Standards:
In May 2014, the FASB issued ASU 2014-09, "Revenue from Contracts with Customers," (ASU 2014-09), which creates a new Topic, Accounting Standards Codification Topic 606. The standard is principle-based and provides a five-step model to determine when and how revenue is recognized. The core principle of ASU 2014-09 is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The accounting standard is effective for annual and interim periods beginning after December 15, 2016. Early adoption is not permitted. The Company is currently evaluating the impact of adopting this guidance.

CASH_AND_CASH_EQUIVALENTS

CASH AND CASH EQUIVALENTS	12 Months Ended
	Dec. 31, 2014
CASH AND CASH EQUIVALENTS [Abstract]
CASH AND CASH EQUIVALENTS	NOTE 3:-       CASH AND CASH EQUIVALENTS
		December 31,
			2014		2013
	Bank deposits in U.S. dollars (bearing an annual average interest rate of 0.22% for 2013)	$	-	$	24,731
	Bank deposits in NIS (bearing an annual average interest rate of 1.32% for 2013)		-		1,441
	Cash in banks		25,643		2,579
		$	25,643	$	28,751

OTHER_ACCOUNTS_RECEIVABLE_AND_

OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES	12 Months Ended
	Dec. 31, 2014
OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES [Abstract]
OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES	NOTE 4:-       OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES
		December 31,
			2014		2013
	Prepaid expenses		501		492
	Government authorities		58		1,172
	Accrued interest		143		57
	Receivables from foreign currency derivative contracts		141		-
	Other		15		10
		$	858	$	1,731

PROPERTY_AND_EQUIPMENT_NET

PROPERTY AND EQUIPMENT, NET	12 Months Ended
	Dec. 31, 2014
PROPERTY AND EQUIPMENT, NET [Abstract]
PROPERTY AND EQUIPMENT, NET	NOTE 5:-       PROPERTY AND EQUIPMENT, NET
		December 31,
			2014		2013
	Cost:
	Computers, software and related equipment	$	5,429	$	5,139
	Laboratory equipment and office furniture		6,038		4,219
	Leasehold improvements		739		668
			12,206		10,026
	Accumulated depreciation:
	Computers, software and related equipment		5,100		4,978
	Laboratory equipment and office furniture		3,770		3,281
	Leasehold improvements		606		559
			9,476		8,818
	Depreciated cost	$	2,730	$	1,208
	For the years ended December 31, 2014, 2013 and 2012, depreciation expenses were approximately $ 658, $ 370 and $ 299, respectively.

OTHER_ACCOUNTS_PAYABLE_AND_ACC

OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES	12 Months Ended
	Dec. 31, 2014
OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES [Abstract]
OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES	NOTE 6:-       OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES
		December 31,
		2014		2013
	Employees and related accruals	$	1,234	$	626
	Consultants and board of directors members		353		314
	Accrual for OCS royalties payment		289		120
	Accrued expenses		992		663
	Other		18		5
		$	2,886	$	1,728

RESEARCH_AND_DEVELOPMENT_FUNDI

RESEARCH AND DEVELOPMENT FUNDING ARRANGEMENTS AND OTHERS	12 Months Ended
	Dec. 31, 2014
RESEARCH AND DEVELOPMENT FUNDING ARRANGEMENT [Abstract]
RESEARCH AND DEVELOPMENT FUNDING ARRANGEMENT	NOTE 7:-      RESEARCH AND DEVELOPMENT FUNDING ARRANGEMENT
	The following table summarizes the balances recorded on the Company's financial statements with respect to the research and development funding arrangements:
		December 31,
		2014				2013
	Embedded Derivatives	$	-		$	12,431
	Research and Development Component		421			758
		$	421		$	13,189
	a. On December 29, 2010, the Company entered into a Funding Agreement (the “Original Pipeline Funding Agreement”) with Baize Investments (Israel) Ltd. (“Baize”), pursuant to which Baize provided the Company with $ 5,000 in support of the Company's therapeutic product candidates in research and development.  On December 20, 2011, the Company also entered into a mAb Funding Agreement with Baize, pursuant to which Baize agreed to invest $ 8,000 in connection with certain research funding for certain  mAb product candidates.  This agreement was amended on July 24, 2012 and December 27, 2012 (as amended, the “mAb Funding Agreement”).
	As part of the mAb Funding Agreement the Company granted, 100,000 options to an agent and cash payment of $ 80. Based on ASC 505, the Company recorded the options as a liability at fair value and re-measured the liability at each cut-off period. During the year ended December 31, 2013 and 2012 the Company recorded financial income of $ 104 and $ 20, respectively in the consolidated statements of comprehensive loss.
	In April 2013, following receipt of the final funding amount under the mAb Funding Agreement and grant of the options to an agent, the remaining re-measured outstanding liability was classified to the Company's additional-paid-in-capital.
	On April 21, 2013, the Company entered with Baize into an amendment to the funding agreements, pursuant to which the mAb Funding Agreement was terminated and the Original Pipeline Funding Agreement was amended (the “Amended Pipeline Funding Agreement”) as follows.
	•      Until June 30, 2015, Baize had the right to receive 10% of the cash consideration received by the Company or its affiliates from third parties, less certain pass-through amounts, with respect to the “Combined Program Initial Candidates” (“Amended Initial Participation Rights”). The Combined Program Initial Candidates included (i) the five designated product candidates from the Original Pipeline Funding Agreement and (ii) all mAb product candidates to be developed against the eight specified Targets from the mAb Funding Agreement.
	•        Not later than June 30, 2015 or, if later, 30 days following the receipt by Baize from the Company of the annual report for 2014 containing a status report with respect to the Combined Program Initial Candidates Baize was required to select five product candidates from the Combined Program Initial Candidates, as “Selected Products.”
	•        Beginning July 1, 2015 through December 31, 2030, Baize was to have the right to receive 10% of the cash consideration received by the Company or its affiliates from third parties, less certain pass-through amounts, with respect to the five Selected Products (the “Amended Final Participation Rights”, together with the Amended Initial Participation Rights, the "Amended Participation Rights").
	•       Baize had the right at any time until June 30, 2015 to exchange the Amended Participation Rights for a number of the Company's ordinary shares to be calculated as the quotient of (i) $ 13,000 less 50% of any cash consideration paid to Baize as Amended Participation Rights, divided by (ii) the average closing price of the Company's ordinary shares during the twenty (20) trading days prior to the Actual Exchange Date (the “Exchange Price”); provided however that the Exchange Price was not to be lower than $ 3.00 per share, and was not to exceed $ 12.00 per share.
	•       The warrant granted to Baize to purchase up to 500,000 of the Company's ordinary shares with original exercise price of $ 6.00 (“Detachable Warrants”) under the Original Pipeline Funding Agreement was terminated, and the Company had issued Baize a new warrant (the “2013 Warrant”) to purchase up to 500,000 of the Company's ordinary shares, exercisable at $ 7.50 per share through June 30, 2015.
	b.      In accordance with ASC 730-20, "Research and Development Arrangements" and ASC 815, "Derivative and Hedging" the Company considered the Participation Rights of the instrument issued to be a research and development arrangement ("Research and Development Component") coupled with embedded derivatives (that are the Conversion Alternative and the Participation Rights ) as those instruments do not have fixed settlement provisions.
	Consequently, the Company determined that the embedded derivatives in the Research and Development Component should be accounted for as a liability to be measured at fair value at inception. The embedded derivatives will be re-measured to fair value at each reporting period until their exercise or expiration with the change in such calculated value reported in the statement of operations (as part of financial income or expenses). As a result, the fair value of those embedded derivatives would be bifurcated out of the amount to be allocated to the Research and Development Component.
	The Company has further determined that the Detachable Warrants should be accounted for and classified as an equity component since the warrants have fixed settlement provisions as stated above.
	As of December 31, 2013 and 2012, the Company re-measured the embedded derivatives in the Research and Development Component and recorded an accumulated $ 811 and $ 588 as financial expenses, respectively in the consolidated statements of comprehensive loss.
	The Research and Development Component was calculated as residual between the payments received and the embedded derivatives (as mentioned above), recorded at cost and has been amortized over the period in which the development is being provided in connection with the relevant designated product candidates as deduction from research and development expenses in the consolidated statements of comprehensive loss. As of December 31, 2014 and 2013 the Research and Development Component amounted of $ 421 and $ 758. During the years ended December 31, 2014, 2013 and 2012 the Company amortized the Research and Development Component within research and development funding arrangement in the total amount of $ 337, $ 230 and $ 130, respectively.
	c. On August 20, 2014, the Company entered with Baize into the Termination and Equity Conversion Agreement (the “2014 Baize Agreement”) pursuant to which:
	•    The Amended Pipeline Funding Agreement, including all rights to receive the Amended Participation Rights and all rights to receive information concerning the Combined Program Initial Candidates, has been terminated.
	•      The 2013 Warrant has been terminated.
	•      The Company issued to Baize 1,600,000 of its ordinary shares, par value NIS 0.01 per share.
	•      Until December 31, 2015, Baize has the right to receive 5% of the cash consideration received by the Company or its affiliates from third parties, less certain pass-through amounts, with respect to the Combined Program Initial Candidates.
	d.        The Company selected the Monte Carlo Simulation model as the methodology for determining the fair value for the embedded derivatives.
	These option-pricing models require a number of assumptions, of which the most significant are the expected share price volatility and the expected term.
	In estimating the embedded derivatives' fair value, the Company used the following assumptions:
		August 20,				December 31,
		2014
						2013
		Amended Funding Arrangement
	Risk-free interest rate (1)		0.09	%			0.25	%
	Expected volatility (2)		57.76	%			55.65	%
	Expected life (in years) (3)		0.84				1.5
	Expected dividend yield (4)		0				0
	(1)  Risk-free interest rate – based on the yields from U.S. treasury bonds with equivalent terms.
	(2)  Expected volatility - was calculated based on actual historical share price movements of the Company over a term that is equivalent to the expected term of the embedded derivative.
	(3)  Expected life - the expected life of the conversion feature was based on the term of the embedded derivative.
	(4)  Expected dividend yield - was based on the fact that the Company has not paid dividends to ordinary shareholders in the past and does not expect to pay dividends to ordinary shareholders.
	e.       For the year ended December 31, 2014 the Company re-measured the embedded derivatives in the Research and Development Component and recorded an accumulated $ 269 as financial income in the consolidated statements of comprehensive loss. As a result of the 2014 Baize Agreement the Company recorded financial expenses of $ 792 in the consolidated statements of comprehensive loss.

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2014
COMMITMENTS AND CONTINGENCIES [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 8:-      COMMITMENTS AND CONTINGENCIES
	a.        The Company and Compugen Inc. lease their facilities and motor vehicles under various operating lease agreements that expire on various dates.
	Annual minimum future rental commitments under non-cancelable operating leases are approximately as follows:
	December 31,
	2015	$	908
	2016		592
	2017		561
	2018		269
		$	2,330
	Operating lease expenses for the Company and Compugen Inc. were approximately $ 791, $ 724 and $ 633 in the years ended December 31, 2014, 2013 and 2012, respectively.
	b.       The Company provided bank guarantees in the amount of $ 543 in favor of its offices' lessor in Israel, foreign currency derivative contracts, credit card security for its U.S. subsidiary and check deposit in the amount of $ 74 in favor of its offices' lessor in California, U.S.
	c.       Under the OCS royalty-bearing programs, the Company is not obligated to repay any amounts received from the OCS if it does not generate any income from the results of the funded research program(s). If income is generated from a funded research program, the Company is committed to pay royalties at a rate of between 3% to 5% of future revenue arising from such research program(s), and up to a maximum of 100% of the amount received, linked to the U.S. dollar (for grants received under programs approved subsequent to January 1, 1999, the maximum to be repaid is 100% plus interest at LIBOR). For the years ended December 31, 2014 and 2013, the Company has an aggregate of paid and accrued royalties to the OCS, recorded as cost of revenue in the consolidated statement of comprehensive loss, in the amount of $ 433 and $ 126, respectively. For the year ended December 31, 2012 the Company incurred no obligation to pay or accrue any amounts to the OCS.
	As of December 31, 2014, the Company's aggregate contingent obligations for payments to OCS, based on royalty-bearing participation received or accrued, net of royalties paid or accrued, totaled approximately to $ 8,899.
	d. Under the Israel-U.S. Binational Industrial Research and Development (" BIRD") plan, the Company is not obligated to repay any amounts previously received from BIRD if it does not generate any income from the outcome of the funded research program. As of December 31, 2014 the Company accounted for proceeds under BIRD plan in total aggregate amount of approximately $ 500, received in the period between December 2005 and March 2012. As of December 31, 2014 and 2013 the Company does not expect any income to be generated from the outcome of the funded research BIRD plan and as such no obligation was recorded.
	e.      On June 25, 2012 the Company and its U.S subsidiary entered into an Antibodies Discovery Collaboration Agreement (the " Antibodies Discovery Agreement") with a U.S. antibody technology company ("mAb Technology Company"), providing an established source for fully human mAbs. Under the Antibodies Discovery Agreement the mAb Technology Company will be entitled to certain royalties that could be eliminated, upon payment of certain one-time fees (all payments referred together as "Contingent Fees"). As of December 31, 2014 and 2013 the Company did not incur any obligation for such Contingent Fees.
	f.       As mentioned in Note 7, the Company is obligated for certain Participation Rights payments. For the years ended December 31, 2014 and 2013, the Company has an aggregate of paid and accrued payments recorded as cost of revenue in the consolidated statement of comprehensive loss in the amount of $ 263 and $ 616, respectively.
	g.       On May 9, 2012, the Company entered into agreement (the "May 2012 Agreement") with a U.S. Business Development Strategic Advisor ("Advisor") for the purpose of entering into transactions with Pharma companies related to selected Pipeline Program Candidates. Under the agreement the Advisor shall be entitled to at least 4% of the cash considerations that may be received under such transactions as well as a retainer fee of $ 5 per month.
	On February 27, 2014, the Company entered into a new agreement (the "New Agreement") (replacing the May 2012 Agreement, which is terminated on that date) with the Advisor for certain services with respect to financing, strategic and other agreements. Under the New Agreement the Advisor shall be entitled to up to 1% of cash considerations that may be received under financing agreements and a fee that will be determined in good faith in respect to all other transactions.
	For the year ended December 31, 2014 and 2013, the Company has an aggregate of paid and accrued payments recorded as marketing and business development expenses in the consolidated statement of comprehensive loss in the amount of $ 209 and $ 267, respectively.
	For the year ended December 31, 2014 the Company recorded issuance expenses in the amount of $ 725 in respect to fees paid to the Advisor for the public offering which took place in March 2014.

SHAREHOLDERS_EQUITY

SHAREHOLDERS' EQUITY	12 Months Ended
	Dec. 31, 2014
SHAREHOLDERS' EQUITY [Abstract]
SHAREHOLDERS' EQUITY	NOTE 9:-     SHAREHOLDERS' EQUITY
	a.       Ordinary shares:
	The ordinary shares confer upon their holders the right to attend and vote at general meetings of the shareholders. Subject to the rights of holders of shares with limited or preferred rights which may be issued in the future, the ordinary shares of the Company confer upon the holders thereof equal rights to receive dividends,  and to participate in the distribution of the assets of the Company upon its winding-up, in proportion to the amount paid up or credited as paid up on account of the nominal value of the shares held by them respectively and in respect of which such dividends are being paid or such distribution is being made, without regard to any premium paid in excess of the nominal value, if any.
	b. Issuance of shares:
	On August 30, 2011 , the Company entered into an agreement with a sales agent, to issue and sell up to 6,000,000 ordinary shares under an At-the-Market offering ("ATM") program with gross proceeds of up to $ 40,000 pursuant to the Company's effective shelf registration statement on Form F-3 (File No. 333-171655). During the year ended December 31, 2014 the Company issued 363,090 ordinary shares for a total consideration of approximately $ 3,801, net of issuance expenses. On January 21, 2014, the registration statement under which the Company had been selling ordinary shares pursuant to the ATM program terminated.
	On February 28, 2014 ("Grant Date"), the Company entered into an underwriting agreement ("Agreement") related to a public offering of 6,000,000 of its ordinary shares, at public offering price of $ 10.50 per share, less underwriting discounts and commissions of $ 5,533 ("Offering"). Under the terms of the Agreement, the Company granted the underwriters an option, exercisable for 30 days, to purchase up to an additional 900,000 ordinary shares at the same price per share (in total fair value of $ 1,576 as of the Grant Date).
	On March 5, 2014, following the closing of the Offering, the Company issued 6,900,000 ordinary shares, including 900,000 shares sold pursuant to the full exercise of the underwriters' option to purchase additional shares, for a total consideration of approximately $ 66,917, net of issuance expenses.
	c.       Share option plans:
	Under the Company's 2000 and 2010 Share Option Plans as amended ("the Plan"), options may be granted to employees, directors and non-employees of the Company and Compugen Inc.
	Pursuant to the Plan, the Company reserved for issuance up to an aggregate of 18,977,240 ordinary shares. As of December 31, 2014, an aggregate of 3,925,677 options of the Company are still available for future grant.
	In general, options granted under the Plan vest over a four-year period and expire 10 years from the date of grant and are granted at an exercise price of not less than the fair market value of the Company's ordinary shares on the date of grant, unless otherwise determined by the Company's board of directors. The exercise price of the options granted under the plans may not be less than the nominal value of the shares into which such options are exercised and the expiration date may not be later than 10 years from the date of grant. If a grantee leaves his or her employment or other relationship with the Company, or if his or her relationship with the Company is terminated without cause (and other than by reason of death or disability, as defined in the Plan), the term of his or her unexercised options will generally expire in 90 days, unless determined otherwise by the Company's board of directors.
	Any options that are cancelled or forfeited before expiration become available for future grants.
	Transactions related to the grant of options to employees and directors under the above plans during the year ended December 31, 2014, were as follows:
			Number of			Weighted			Weighted			Aggregate
			options			average			average			intrinsic
						exercise			remaining contractual			value
						price			life
						$			Years			$
	Options outstanding at beginning of year		5,628,653			3.76			7.07			29,232
	Options granted		1,172,350			8.76						63
	Options exercised		(336,289	)		3.46						2,119
	Options expired		(756	)		3.43						4
	Options forfeited		(199,588	)		6.09						545
	Options outstanding at end of year		6,264,370			4.64			6.74			23,627
	Options vested and expected to vest at end of year		6,091,709			4.59			6.68			23,227
	Exercisable at end of year		3,243,863			3.19			5			16,668
	Weighted average fair value of options granted to employees and directors during the years 2014, 2013 and 2012 was $ 4.17, $ 3.83 and $ 2.70 per share, respectively.
	The aggregate intrinsic value in the table above represents the total intrinsic value (the difference between the Company's closing share price on the last trading day of calendar 2014 and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their options on December 31, 2014. This amount is impacted by the changes in the fair market value of the Company's shares.
	d.       Options to non-employees:
			Year ended December 31, 2014
			Number of options			Weighted			Weighted
						average			average
						exercise			remaining contractual
						price			life
						$			Years
	Options outstanding at beginning of year		416,500			5.23			3.6
	Options granted		113,000			8.47
	Options exercised		(53,000	)		4.9
	Options expired		(8,334	)		5.45
	Options forfeited		(1,666	)		5.45
	Options outstanding at end of year		466,500			5.71			3.75
	Options vested and expected to vest at end of year		466,500			5.71			3.75
	Exercisable at end of year		392,680			6.04			3.53
	The options are re-measured using a Black-Scholes option-pricing model at their then-current fair value at the last date of each reporting period and compensation cost is adjusted for the changes for those fair values. The Company recognized the compensation cost using the straight-line method.
	The Company used the following weighted-average assumptions for general options granted to non-employees:
		Year ended December 31,
		2014			2013			2012
	Volatility	64	%		67	%		75	%
	Risk-free interest rate	1.77	%		1.03	%		0.66	%
	Dividend yield	0	%		0	%		0	%
	Expected life (years)	5.7			4.5			4.3
	As of December 31, 2014, the total unrecognized estimated compensation cost related to non-vested share options granted prior to that date was $ 7,083 which is expected to be recognized over a weighted average period of approximately 2.46 years.
	The stock-based compensation expenses are included as follows in the expense categories:
		Year ended December 31,
		2014				2013				2012
	Cost of revenue	$	399			$	320			$	59
	Research and development expenses, net		1,862				1,724				1,239
	Marketing and business development expenses		162				151				192
	General and administrative expenses		1,210				1,348				979
		$	3,633			$	3,543			$	2,469
	e.         On July 15, 2013, the Company's compensation committee and board of directors resolved to recommend before the shareholders to grant to the Company's chairman of the board of directors and to its President and CEO options to purchase 60,000 and 120,000 shares, respectively, at an exercise price of $ 5.445 per share, which was the market share price at such date.
	On September 17, 2013 the shareholders of the Company approved this grant. The options shall vest on a monthly basis over a period of 12 months commencing January 1, 2016.
	The pricing model for the award was estimated using a Binomial model with the following assumptions: risk-free interest rate of 2.96%, dividend yields of 0%, expected volatility of 70%% , expected term of the options range between 3.78 - 5.46 years, post-vesting termination rate of 0.51% and suboptimal exercise factor range between 1 - 2.11 factoring rate.
	Consequently, during the year ended December 31, 2014 and 2013 the Company recorded stock-based compensation expenses amounted of $ 348 and $ 108, respectively, as part of its general and administrative expenses.
f.          On March 30, 2014, the Company's Compensation Committee and board of directors resolved to recommend before the shareholders to grant to the Company's chairman of the board of directors and its President and CEO options to purchase 50,000 and 100,000 shares, respectively.
On August 7, 2014 the shareholders of the Company approved this grant, at an exercise price of $ 10.07 per share, which was the market share price at such date. The options shall vest on a monthly basis over a period of 12 months commencing January 1, 2017.

INCOME_TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2014
INCOME TAXES [Abstract]
INCOME TAXES	NOTE 10:-     INCOME TAXES
	g.       Israeli taxation
	1.       Tax rates applicable to the income of the Company.
	2.       Taxable income of the Company is subject to a corporate tax rate as follow: 2012 and 2013 - 25% and 2014 and thereafter - 26.5%.
	3.       Tax benefits under the Law for the Encouragement of Capital Investments, 1959 (the "Law"):
	According to the Law, the Company is entitled to various tax benefits by virtue of the "approved enterprise" and/or "beneficiary enterprise" status granted to part of their enterprises, as implied by this Law. The principal benefits by virtue of the Law are:
	According to the provisions of the Law, the Company has chosen to enjoy the "Alternative" track. Under this track, the Company is tax exempt in the first two years of the benefit period and subject to tax at the reduced rate of 10% - 25% for a period of several years for the remaining benefit period.
	Another condition for receiving the benefits under the alternative track is a minimum qualifying investment. The Company was eligible under the terms of minimum qualifying investment and elected 2006, 2009 and 2012 as its "years of election".
	The income qualifying for tax benefits under the alternative track is the taxable income of a company that has met certain conditions as determined by the Law ("a beneficiary company"), and which is derived from an industrial enterprise. The Law specifies the types of qualifying income that is entitled to tax benefits under the alternative track with respect of an industrial enterprise.
	The benefit period starts with the first year the beneficiary enterprise earns taxable income, provided that 14 years have not passed since the approval was granted and 12 years have not passed since the enterprise began operating. In respect of expansion programs pursuant to Amendment No. 60 to the Law, the benefit period starts at the later of the year elected and the first year the Company earns taxable income provided that 12 years have not passed since the beginning of the year of election. The respective benefit period has not yet begun.
	The above benefits are conditional upon the fulfillment of the conditions stipulated by the Law, regulations published thereunder and the letters of approval for the investments in the approved enterprises, as above.
	Non-compliance with the conditions may cancel all or part of the benefits and refund of the amount of the benefits, including interest. The management believes that the Company is meeting the aforementioned  conditions.
	The Company is also a "foreign investors' company", as defined by the Capital Investments Law, and, as such, is entitled to a 10-year period of benefits and may be entitled to reduced tax rates of between 10% -  25% (depending on the percentage of foreign ownership in each tax year).
	Income from sources other than the "Approved Enterprise" and "Beneficiary Enterprise" during the benefit period will be subject to the tax at the regular tax rate.
	Amendments to the Law:
	In December 2010, the "Knesset" (Israeli Parliament) passed the Law for Economic Policy for 2011 and 2012 (Amended Legislation), which prescribes, among others, amendments to the Law. The amendment  became effective as of January 1, 2011. According to the amendment, the benefit tracks in the Law were modified and a flat tax rate applies to a company's preferred income. The Company will be able to opt to  apply (the waiver is non-recourse) the amendment and from then on it will be subject to the amended tax rates that are: 2011 and 2012 - 15% (in development area A - 10%), 2013 and 2014 - 12.5% (in  development area A - 7%) and in 2015 and thereafter - 12% (in development area A - 6%).
	On July 29, 2013, the Israeli Parliament approved the Amended Budget Law which, among others, cancels the reduction of the tax rates applicable to preferred enterprises (9% in development area A and 16% in  other areas), taxes revaluation gains and increases the tax rates on dividends within the scope of the Law for the Encouragement of Capital Investments to 20% effective from January 1, 2014.
	The Company estimates that the effect of the change in tax rates will not lead to material change in the amounts in the consolidated financial statements.
	1.       Tax benefits under the Law for the Encouragement of Industry (Taxation), 1969:
	Management believes that the Company currently qualifies as an "industrial company" under the above law and as such, enjoys tax benefits, including:
	a)       Deduction of purchase of know-how and patents and/or right to use a patent over an eight-year period;
	b)       The right to elect, under specified conditions, to file a consolidated tax return with additional related Israeli industrial company and an industrial holding company;
	c)       Accelerated depreciation rates on equipment and buildings; and
	d)       The right to claim public issuance expenses over three years, as a deduction for tax purposes.
	The Company believes that currently is qualified as an "industrial company" under the above law and, as such, is entitled to certain tax benefits, mainly accelerated depreciation of machinery and equipment, and the right to claim public issuance expenses over three years, as a deduction for tax purposes.
	2.       Net operating losses carryforward and capital loss:
	As of December 31, 2014, Compugen Ltd.'s net operating losses carryforward for tax purposes in Israel amounted to approximately $ 167,255. These net operating losses may be carried forward indefinitely and may be offset against future taxable income.
	h.        Non-Israeli subsidiary, Compugen Inc.:
	Compugen Inc. is subject to U.S. income taxes. The tax rates are compounded from a progressive federal tax of 35% in addition to a state and local taxes.
	As of December 31, 2014, Compugen Inc. has net operating loss carryforwards for federal income tax purposes of approximately $ 14,455 which expires in the years 2019 to 2032. Utilization of the U.S. net  operating losses may be subject to substantial annual limitation due to the "change in ownership" provisions of the Internal Revenue Code of 1986 and similar state provisions. The annual limitation may result  in the expiration of net operating losses before utilization.
	i.         Loss (income) before taxes is comprised as follows:
		Year ended December 31,
		2014			2013			2012
	Domestic (Israel)	$	11,138		$	13,859		$	13,370
	Foreign		(404	)		(276	)		258
		$	10,734		$	13,583		$	13,628
	j.        Taxes on income are comprised from withholding tax payments amounted of $ 360 which was deducted from milestone payments of $ 7,200 (see also Note 1b) by the German tax authorities.
	k.       Deferred taxes:
	Deferred taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The Company and Compugen Inc.'s deferred tax assets are comprised of operating loss carryforward and other temporary differences. Significant components of the Company and Compugen Inc. deferred tax assets are as follows:
		December 31,
			2014			2013
	Operating loss carryforward	$	49,238		$	52,092
	Research and development credit		4,018			3,265
	Accrued social benefits and other		1,183			182
	Property and equipment		(365	)		-
	Deferred tax asset before valuation allowance		54,074			55,539
	Valuation allowance		(54,074	)		(55,539	)
	Net deferred tax asset	$	-		$	-
	The Company and Compugen Inc. have provided full valuation allowances in respect of deferred tax assets resulting from operating loss carryforward and other temporary differences. Management currently believes that since the Company and Compugen Inc. have a history of losses it is more likely than not that the deferred tax regarding the operating loss carryforward and other temporary differences will not be realized in the foreseeable future.
	l.        Reconciliation of the theoretical tax expense (benefit) to the actual tax expense (benefit):
	The main reconciling items between the statutory tax rate of the Company and the effective tax rate are the non-recognition of tax benefits from accumulated net operating losses carryforward among the Company and Compugen Inc. due to the uncertainty of the realization of such tax benefits.

FAIR_VALUE_MEASUREMENTS

FAIR VALUE MEASUREMENTS	12 Months Ended
	Dec. 31, 2014
FAIR VALUE MEASUREMENTS [Abstract]
FAIR VALUE MEASUREMENTS	NOTE 11:-     FAIR VALUE MEASUREMENTS
	In accordance with ASC 820 "Fair Value Measurements and Disclosures", the Company measures its Investment in Evogene, foreign currency derivative contracts and embedded derivatives in connection with research and development funding arrangement at fair value. Investment in Evogene is classified within Level 1 because this asset is valued using quoted market prices. Foreign currency derivative contracts are classified within Level 2 as the valuation inputs are based on quoted prices and market observable data of similar instruments. Embedded derivatives are classified within Level 3 because they are valued using valuation techniques. Some  of the inputs to these models are unobservable in the market and are significant.
	The Company's financial assets and liabilities measured at fair value on a recurring basis, excluding accrued interest components, consisted of the following types of instruments as of the following dates:
		31-Dec-14
		Fair value measurements
	Description	Fair value			Level 1		Level 2		Level 3
	Investment in Evogene	$	1,054		$	1,054	$	-	$	-
	Foreign currency derivative contracts		141			-		141		-
	Total financial assets	$	1,195		$	1,054	$	141	$	-
		31-Dec-13
		Fair value measurements
	Description	Fair value			Level 1		Level 2		Level 3
	Investment in Evogene	$	4,565		$	4,565	$	-	$	-
	Embedded Derivatives		(12,431	)		-		-		(12,431	)
	Fair value measurements using significant unobservable inputs (Level 3):
			Fair value
			of embedded derivatives
	Balance at January 1, 2013 *)	$	6,864
	Fair value of Exchange Option within the proceeds under the mAb Funding Agreement		4,756
	Change in fair value of Exchange Option and embedded derivatives within research and development arrangement		811
	Balance at December 31, 2013 *)		12,431
	Change in fair value of Exchange Option and embedded derivatives within research and development arrangement		(269	)
	Issuance of shares in respect to Termination and Equity Conversion Agreement		(12,162	)
	Balance at December 31, 2014	$	-
	*)       The amount on the balance sheet of the research and development funding arrangement includes also Research and Development Component of $ 421 and $ 758 as of December 31, 2014 and 2013, respectively, and fair value of liability with respect to outstanding options to non-employee, as mentioned below.
			Fair value
			of outstanding options to non- employee
	Balance at January 1, 2013	$	264
	Change in fair value of liability with respect to outstanding options to non- employee		(104	)
	Classification of portion liability with respect to outstanding options to non-employee to additional paid in capital		(160	)
	Balance at December 31, 2013		-

GEOGRAPHIC_INFORMATION_AND_MAJ

GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS	1 Months Ended
	Jan. 21, 2014
GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS [Abstract]
GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS	NOTE 12:-    GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS
	The Company's business is currently comprised of one operating segment, the research, development and commercialization of therapeutic and product candidates. The nature of the products and services provided by the Company and the type of customers for these products and services are similar. Operations in Israel and the United States include research and development, sales and business development. The Company follows  ASC 280, "Segment Reporting."  Total revenues are attributed to geographic areas based on the location of the end customer.
	The following represents the total revenue for the years ended December 31, 2014, 2013 and 2012 and long-lived assets as of December 31, 2014 and 2013:
		Year ended December 31,
			2014			2013			2012
	Revenue from sales to customers:
	Israel	$	212		$	260		$	242
	Europe		12,155			3,289			-
	Total revenue	$	12,367		$	3,549		$	242
		December 31,
			2014			2013
	Long-lived assets:
	Israel	$	1,217		$	567
	United States		1,513			641
	Total long-lived assets	$	2,730		$	1,208
		Year ended December 31,
			2014			2013			2012
	Sales to a single customer exceeding 10%:
	Customer A		98	%		93	%		100	%

FINANCIAL_INCOME_LOSS_NET

FINANCIAL INCOME (LOSS), NET	12 Months Ended
	Dec. 31, 2014
FINANCIAL INCOME (LOSS), NET [Abstract]
FINANCIAL INCOME (LOSS), NET	NOTE 13:-     FINANCIAL INCOME (LOSS), NET
		Year ended December 31,
			2014			2013			2012
	Interest income	$	346		$	169		$	301
	Bank fees and other finance expenses		(16	)		(28	)		(61	)
	Change in fair value of research and development funding arrangement		269			(811	)		(588	)
	Change in fair value of liability with respect to outstanding options to non-employee		-			104			20
	Loss in respect to Termination and Equity Conversion Agreement		(792	)
	Gain from sales of marketable securities		2,345			3,711			-
	Foreign currency translation adjustments		(394	)		315			242
	Financial income (loss), net	$	1,758		$	3,460		$	(86	)

RELATED_PARTY_BALANCES_AND_TRA

RELATED PARTY BALANCES AND TRANSACTIONS	12 Months Ended
	Dec. 31, 2014
RELATED PARTY BALANCES AND TRANSACTIONS [Abstract]
RELATED PARTY BALANCES AND TRANSACTIONS	NOTE 14:-   RELATED PARTY BALANCES AND TRANSACTIONS
	The Company provides research and development services to Neviah in consideration for pre-scheduled determined fees. As of December 31, 2014, 2013 and 2012 the Company recognized revenue from the agreement with Neviah in total amount of $ 212, $ 260 and $ 242, respectively.

LOSSES_PER_SHARE

LOSSES PER SHARE	12 Months Ended
	Dec. 31, 2014
LOSSES PER SHARE [Abstract]
LOSSES PER SHARE	NOTE 15:-    LOSSES PER SHARE
	The following table sets forth the computation of basic and diluted losses per share:
		Year ended December 31,
			2014			2013			2012
	Numerator:
	Net loss for basic loss per share	$	(11,094	)	$	(14,083	)	$	(13,628	)
	Loss in respect to change in fair value of research and development funding arrangement		(1,295	)		-			(16	)
	Net loss for basic loss per share	$	(12,389	)	$	(14,083	)	$	(13,644	)
	Denominator:
	Weighted average number of ordinary shares used in computing basic net loss per share		47,808,855			38,869,438			35,844,496
	Dilutive average number of ordinary shares in respect to research and development funding arrangement		578,208			-			404,766
	Weighted average number of ordinary shares used in computing diluted net loss per share		48,387,063			38,869,438			36,249,262
	Diluted earnings per ordinary share	$	(0.26	)	$	(0.36	)	$	(0.38	)

SIGNIFICANT_ACCOUNTING_POLICIE1

SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2014
SIGNIFICANT ACCOUNTING POLICIES [Abstract]
Use of estimates:	a.      Use of estimates:
	The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions. The Company's management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Financial statements in U.S. dollars:	b.      Financial statements in U.S. dollars:
	The functional currency of the Company is the U.S. dollar, as the Company's management believes that the U.S. dollar is the primary currency of the economic environment in which the Company and Compugen Inc. have operated and expect to continue to operate in the foreseeable future. The majority of the Company's revenues and financing transactions were made in U.S. dollars. The majority of the Company operations are currently conducted in Israel and most of the expenses in Israel are currently paid in new Israeli shekels ("NIS").
	Transactions and balances denominated in U.S. dollars are presented at their original amounts. Monetary accounts denominated in currencies other than the dollar are re-measured into dollars in accordance with ASC No. 830, "Foreign Currency Matters". All transaction gains and losses of the re-measurement of monetary balance sheet items are reflected in the consolidated statement of comprehensive loss as financial income or expenses, as appropriate.
Basis of consolidation:	c.      Basis of consolidation:
	The consolidated financial statements include the accounts of the Company and Compugen Inc., Intercompany transactions and balances have been eliminated upon consolidation.
Cash equivalents:	d.      Cash equivalents:
	Cash equivalents are short-term highly liquid investments that are readily convertible to cash with original maturities of three months or less at acquisition.
Restricted cash:	e.      Restricted cash:
	Restricted cash held in interest bearing saving accounts which are used as a security for the Company's Israeli facilities leasehold bank guarantee, foreign currency derivative contracts, and credit card security for Compugen Inc.
Short-term bank deposits	f.      Short-term bank deposits
	Bank deposits with maturities of more than three months but less than one year are included in short-term bank deposits. Such short-term bank deposits are stated at cost which approximates market values.
	The short-term bank deposits as of December 31, 2014 and 2013 are in U.S. dollar and bear an annual average interest rate of 0.85% and 0.63%, respectively.
Marketable securities:	g.      Marketable securities:
	The Company accounts for its investment in Evogene Ltd. ("Evogene") in accordance with ASC No. 320, "Investments - Debt and Equity Securities".
	Management determines the appropriate classification of its investments at the time of purchase and reevaluates such determinations at each balance sheet date.
	The Company classifies its investment in Evogene as available-for-sale securities which are carried at fair value, with the unrealized gains and losses, reported in "accumulated other comprehensive income (loss)" in shareholders' equity. Realized gains and losses on sale of investments are included in "financial income (loss), net" and are derived using the specific identification method for determining the cost of securities.
	The Company recognizes an impairment charge when a decline in the fair value of its investments is below the cost basis of such securities and is judged to be other-than-temporary. Factors considered in making such a determination include the duration and severity of the impairment, the reason for the decline in value, the potential recovery period and the Company's intent to sell, including whether it is more likely than not that the Company will be required to sell the investment before recovery of cost basis. During the years 2014, 2013 and 2012, no impairment losses have been identified.
	As of December 31, 2014 and 2013, the Company holds 113,405 and 232,292 shares representing less than 1% of Evogene outstanding ordinary shares.
Non-current prepaid expenses:	h.      Non-current prepaid expenses:
	Non-current prepaid expenses consist of non-current lease deposits as security for the Compugen Inc.'s facility lease, motor vehicles leases and non-refundable payments for research and developments services (see also Note 8e).
Long-term bank deposits:	i.      Long-term bank deposits:
	Bank deposits with maturities of more than one year are included in long-term bank deposits.
	The long-term bank deposits as of December 31, 2014 are in U.S. dollar and bear an annual average interest rate of 1.02% .The long-term bank deposits matures in the period between May-June 2016.
Property and equipment, net:	j.      Property and equipment, net:
	Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following annual rates:
		%
	Computers, software and related equipment	33
	Laboratory equipment and office furniture	6 - 20 (mainly 20)
	Leasehold improvements	Shorter of the term of the lease or useful life
Impairment of long-lived assets:	k.      Impairment of long-lived assets:
	The long-lived assets of the Company and Compugen Inc. are reviewed for impairment in accordance with ASC 360, "Property, Plant, and Equipment", whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset with the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. During the years 2014, 2013 and 2012, no impairment losses have been identified.
Revenue recognition:	l.      Revenue recognition:
	The Company generates revenue mainly from its Research and Development Collaboration and License Agreement. The revenues are derived mainly from upfront license payments, research and development services and contingent payments related to milestones achievements.
	The Company applies ASC 605-25, "Multiple-Element Arrangements" pursuant to which each required deliverable is evaluated to determine whether it qualifies as a separate unit of accounting based on whether the deliverable has "stand-alone value". The arrangement's consideration that is fixed or determinable is then allocated to each separate unit of accounting based on the relative selling price of each deliverable which is not contingent based on its vendor specific objective evidence (''VSOE'') if available, third party evidence (''TPE'') if VSOE is not available, or estimated selling price (''ESP'') if neither VSOE nor TPE is available.
	Revenues from upfront license payments and research and development services are recognized according to the proportional performance method along the research and development services period in accordance with ASC 605-10, "Revenue Recognition".
	As of December 31, 2014 and 2013 the Company deferred revenues in respect to the upfront license payment amounted to $ 1,789 and $ 6,711, respectively.
	Contingent payments related to milestones achievement and royalties are recognized immediately upon the accomplishment of futures events, in accordance with ASC 605-28, "Revenue Recognition – Milestone Method".
	On June 27, 2014, and October 14, 2014 the Company achieved the first and second substantive milestones with respect to one licensed program, under the Bayer Agreement according to which the Company recognized revenues in total amount of $ 7,200 in accordance with the criteria prescribed under ASC 605-28.
Cost of revenues:	m.      Cost of revenues:
	Cost of revenues consist mainly of research and development expenses attributed to the Research and Development Collaboration and License Agreement, as well as certain royalties paid.
Research and development expenses, net:	n.      Research and development expenses, net:
	Research and development expenses are charged to the statement of comprehensive loss as incurred.
	Royalty and non-royalty bearing grants from the Office of the Chief Scientist of the Israel Ministry of Industry, Trade & Labor ("OCS") and the Bi-national Industrial Research ("BIRD") for funding approved research and development projects, are recognized at the time the Company is entitled to such grants, on the basis of the research and development expenses incurred. Such grants are presented as a reduction from research and development expenses in the consolidated statements of comprehensive loss.
	The Research and Development component, as defined in note 7, is recognized at the time the Company received the payments under research and development funding arrangement, which is calculated as residual between the payments received and the embedded derivatives, and is amortized over the period in which the development is being provided in connection with the relevant designated product candidates. Such component is deducted from research and development expenses in the consolidated statements of comprehensive loss.
Serverance pay:	o.      Severance pay:
	The Company's liability for severance pay for its Israeli employees is calculated pursuant to Israeli Severance Pay Law based on the most recent salary of the employees multiplied by the number of years of employment as of the balance sheet date, and is in large part covered by regular deposits with recognized pension funds, deposits with severance pay funds and purchases of insurance policies. The value of these deposits and policies is recorded as an asset in the Company's balance sheet.
	Pursuant to Section 14 of the Israeli Severance Pay Law, for Israeli employees under this section, the Company's contributions for severance pay have replaced its severance obligation. Upon contribution of the full amount of the employee's monthly salary for each year of service, no additional calculations is conducted between the parties regarding the matter of severance pay and no additional payments is made by the Company to the employee. Further, the related obligation and amounts deposited on behalf of the employee for such obligation are not stated on the balance sheet, as the Company is legally released from the obligation to employees once the deposit amounts have been paid.
	Severance expenses for the years ended December 31, 2014, 2013 and 2012 amounted to approximately $ 344, $ 294 and $ 252, respectively.
Stock-based compensation:	p.      Stock-based compensation:
	The Company accounts for stock-based compensation in accordance with ASC 718, "Compensation - Stock Compensation", ("ASC 718"), which requires companies to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company's consolidated statement of comprehensive loss.
	The Company recognizes compensation expenses for the value of its awards granted based on the straight-line method over the requisite service period of each of the awards, net of estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Estimated forfeitures are based on actual historical pre-vesting forfeitures.
	The Company selected the Black-Scholes-Merton ("Black-Scholes") option-pricing model (except as mentioned in Note 9e) as the most appropriate fair value method for the majority of its share-options awards and values share based on the market value of the underlying shares at the date of grant. The option-pricing model requires a number of assumptions, of which the most significant are the expected share price volatility and the expected option term. Expected volatility was calculated based on actual historical share price movements over a term that is equivalent to the expected term of granted options. The expected term of options granted is based on historical experience and represents the period of time that options granted are expected to be outstanding.
	The risk-free interest rate is based on the yield from U.S. treasury bonds with an equivalent term. The Company has historically not paid dividends and has no foreseeable plans to pay dividends.
	The Company used the following weighted-average assumptions for granted options:
				Year ended December 31,
				2014			2013			2012
	Volatility				56	%		71	%	82	%
	Risk-free interest rate				1.53	%		1.25	%	0.66	%
	Dividend yield				0	%		0	%	0	%
	Expected life (years)				4.7			4.4		4.5
	The Company applies ASC 505-50, "Equity-Based Payments to Non-Employees" ("ASC 505") with respect to options and warrants issued to non-employees which requires the use of option valuation models to measure the fair value of the options and warrants at the measurement date.
Concentration of credit risks:	q.      Concentration of credit risks:
	Financial instruments that potentially subject the Company and Compugen Inc. to concentration of credit risk consist principally of cash and cash equivalents, restricted cash, short-term bank deposits, marketable securities, long-term bank deposits and foreign currency derivative contracts.
	Cash, cash equivalents, restricted cash and short-term bank deposits are invested in major banks in Israel and in the U.S. Generally, these deposits may be redeemed upon demand and bear minimal risk.
	Long-term bank deposits are invested in major banks in Israel. Management believes that the financial institutions that hold the Company's investment are financially sound and, accordingly, minimal credit risk exists with respect to this investment.
	The Company's marketable securities consist of investment in Evogene ordinary shares which are publicly traded in the U.S. and Israel.
Basic and diluted loss per share:	r.      Basic and diluted loss per share:
	Basic loss per share is calculated based on the weighted average number of ordinary shares outstanding during each year. Diluted net loss per share is calculated based on the weighted average number of ordinary shares outstanding during each year, plus dilutive potential in accordance with ASC 260, "Earnings per Share."
	All outstanding share options and warrants for the years ended December 31, 2014, 2013 and 2012 have been excluded from the calculation of the diluted net loss per share because all such securities are anti-dilutive for all periods presented. As of December 31, 2014, 2013 and 2012 the total weighted average number of shares related to outstanding options excluded from the calculations of diluted net loss per share were 6,363,348, 6,271,819 and 6,170,554, respectively. The total weighted average number of shares related to warrants under the research and development funding arrangement excluded from the calculations of diluted net loss per share were 333,333 for the year ended December 31, 2014 and 500,000 for each of the years ended December 31, 2013 and 2012. As of December 31, 2013 the total weighted average number of shares related to the exchange option under the research and development funding arrangement excluded from the calculations of diluted net loss per share was 2,157,293.
Income taxes:	s.      Income taxes:
	The Company accounts for income taxes in accordance with ASC No. 740, "Income Taxes", ("ASC 740") which prescribes the use of the liability method whereby deferred tax asset and liability account balances are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value. As of December 31, 2014 and 2013, a full valuation allowance was provided by the Company.
	ASC 740 contains a two-step approach to recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. As of December 31, 2014 and 2013 no liability for unrecognized tax benefits was recorded as a result of ASC 740.
Fair value of financial instruments:	t.      Fair value of financial instruments:
	The Company applies ASC 820, "Fair Value Measurements and Disclosures" ("ASC 820"), pursuant to which fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the "exit price") in an orderly transaction between market participants at the measurement date.
	In determining fair value, the Company uses various valuation approaches. ASC 820 establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company.
	Unobservable inputs are inputs that reflect the Company's assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances.
	The hierarchy is broken down into three levels based on the inputs as follows:
		Level 1 -	Quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company can access at the measurement date.
		Level 2 -	Valuations based on one or more quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.
		Level 3 -	Valuations based on inputs that are unobservable and significant to the overall fair value measurement.
	The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.
	The carrying amounts of cash and cash equivalents, restricted cash, short-term bank deposits, other accounts receivable, trade payables, and other accounts payable and accrued expenses approximate their fair values due to the short-term maturities of such instruments.
	The Company measures its investment in Evogene, embedded derivatives with respect to research and development funding arrangement, the liability with respect to outstanding options to non-employees and foreign currency derivative contracts at fair value (see also Note 11).
Derivatives instruments:	u.      Derivative instruments:
	The Company accounts for derivatives and hedging based on ASC 815, “Derivatives and Hedging”. ASC 815 requires the Company to recognize all derivatives on the balance sheet at fair value. The accounting for changes in the fair value (i.e., gains or losses) of a derivative instrument depends on whether it has been designated and qualifies as part of a hedging relationship and on the type of hedging relationship. For those derivative instruments that are designated and qualify as hedging instruments, the Company must designate the hedging instrument, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of a net investment in a foreign operation. If the derivatives meet the definition of a hedge and are so designated, depending on the nature of the hedge, changes in the fair value of such derivatives will either be offset against the change in fair value of the hedged assets, liabilities, or firm commitments through earnings, or recognized in other comprehensive income until the hedged item is recognized in earnings. The ineffective portion of a derivative's change in fair value is recognized in earnings.
	The Company entered into forward contracts to hedge against the risk of overall changes in future cash flow from payments of payroll and related expenses as well as other expenses denominated in NIS. As of December 31, 2014, the Company had outstanding forward contracts in the notional amount of $ 5,626. These contracts were for a period of nine months ended September 30, 2015. The Company measured the fair value of the contracts in accordance with ASC 820 (classified as level 2).
	These contracts met the requirement for cash flow hedge accounting and as such during 2014 unrealized gains in the amount of $ 141 were recognized under other comprehensive income, none of the related expenses were incurred and therefore the Company did not classify any of the amount to operating expenses. The fair value of the Company's outstanding forward contracts at December 31, 2015 amounted to unrealized gains of $ 141.
Investments in affiliates:	v.      Investment in affiliates:
	The Company accounts for its investment in affiliated companies under the equity method in accordance with ASC 323, "Investments-Equity Method". For the purpose of these financial statements, an affiliated company is a company held to the extent of 20% or more, or a company less than 20% held, in which the Company can exercise significant influence over operating and financial policy of the affiliate.
	The Company has two investments in affiliates, Neviah Genomics Ltd. ("Neviah") and Keddem BioScience Ltd. ("Keddem"). The Company does not have control over Neviah and Keddem, however has significant influence through holding rights of 25.12% and 36%, respectively. The Company accounts for its investment in Neviah and Keddem under the equity method. Both Neviah and Keddem are in accumulated loss position until December 31, 2014 and because the Company has no commitment to fund Neviah's and Keddem's operations, no investment account was recorded in the Company's consolidated financial statements as of December 31, 2014 and 2013.
	On December 17, 2014 ("Loan Grant Date") the Company, Merck Holdings Netherlands B.V. ("Merck Holdings") and Neviah entered into Convertible Bridge Loan ("Loan") Agreement ("Loan Agreement") in total amount of Euro 500 thousand ("Loan Amount") to finance Neviah's operations. Under the agreement, the Company provided an amount of $ 155 reflecting its respective portion of the Loan Amount. The Loan is granted for a period of 18 months from the Loan Grant Date ("Loan Term") and bear interest at an annual rate of 2%.
	The Loan is automatically converted under certain terms in the event of Qualified Investment or M&A Transaction as defined in the Loan Agreement. In addition if a Qualified Investment does not occur within six months from the Loan Grant Date, the Company may elect to convert the Loan under certain terms as defined in the Loan Agreement.
	Following the financing of the Loan as described above, the Company recorded equity losses of $ 155 in respect to the total amount provided to Neviah.
Comprehensive income (loss):	w.      Comprehensive income (loss):
	The Company accounts for comprehensive income (loss) in accordance with ASC 220, "Comprehensive Income". This statement establishes standards for the reporting and display of comprehensive income (loss) and its components in a full set of general purpose financial statements. Comprehensive income (loss) generally represents all changes in shareholders' equity during the period except those resulting from investments by, or distributions to, shareholders. The Company elected to present the comprehensive income in a single continuous statement. The Company determined that its items of other comprehensive income (loss) relate to unrealized gains on foreign currency derivative contracts and unrealized gains on available- for- sale marketable securities.
New Accounting Pronouncements and Other Standards:	x.      New Accounting Pronouncements and Other Standards:
	In May 2014, the FASB issued ASU 2014-09, "Revenue from Contracts with Customers," (ASU 2014-09), which creates a new Topic, Accounting Standards Codification Topic 606. The standard is principle-based and provides a five-step model to determine when and how revenue is recognized. The core principle of ASU 2014-09 is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The accounting standard is effective for annual and interim periods beginning after December 15, 2016. Early adoption is not permitted. The Company is currently evaluating the impact of adopting this guidance.

SIGNIFICANT_ACCOUNTING_POLICIE2

SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2014
SIGNIFICANT ACCOUNTING POLICIES [Abstract]
Schedule of Depreciation Rates for Property and Equipment		%
	Computers, software and related equipment	33
	Laboratory equipment and office furniture	6 - 20 (mainly 20)
	Leasehold improvements	Shorter of the term of the lease or useful life
Schedule of weighted-average assumptions for granted options			Year ended December 31,
			2014			2013			2012
	Volatility			56	%		71	%		82	%
	Risk-free interest rate			1.53	%		1.25	%		0.66	%
	Dividend yield			0	%		0	%		0	%
	Expected life (years)			4.7			4.4			4.5

CASH_AND_CASH_EQUIVALENTS_Tabl

CASH AND CASH EQUIVALENTS (Tables)	12 Months Ended
	Dec. 31, 2014
CASH AND CASH EQUIVALENTS [Abstract]
Schedule Of Cash And Cash Equivalents		December 31,
			2014		2013
	Bank deposits in U.S. dollars (bearing an annual average interest rate of 0.22% for 2013)	$	-	$	24,731
	Bank deposits in NIS (bearing an annual average interest rate of 1.32% for 2013)		-		1,441
	Cash in banks		25,643		2,579
		$	25,643	$	28,751

OTHER_ACCOUNTS_RECEIVABLE_AND_1

OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES (Tables)	12 Months Ended
	Dec. 31, 2014
OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES [Abstract]
Schedule Of Other Accounts Receivable And Prepaid Expenses		December 31,
			2014		2013
	Prepaid expenses		501		492
	Government authorities		58		1,172
	Accrued interest		143		57
	Receivables from foreign currency derivative contracts		141		-
	Other		15		10
		$	858	$	1,731

PROPERTY_AND_EQUIPMENT_NET_Tab

PROPERTY AND EQUIPMENT, NET (Tables)	12 Months Ended
	Dec. 31, 2014
PROPERTY AND EQUIPMENT, NET [Abstract]
Schedule of Property And Equipment, Net		December 31,
			2014		2013
	Cost:
	Computers, software and related equipment	$	5,429	$	5,139
	Laboratory equipment and office furniture		6,038		4,219
	Leasehold improvements		739		668
			12,206		10,026
	Accumulated depreciation:
	Computers, software and related equipment		5,100		4,978
	Laboratory equipment and office furniture		3,770		3,281
	Leasehold improvements		606		559
			9,476		8,818
	Depreciated cost	$	2,730	$	1,208

OTHER_ACCOUNTS_PAYABLE_AND_ACC1

OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)	12 Months Ended
	Dec. 31, 2014
OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES [Abstract]
Schedule of Other Accounts Payable and Accrued Expenses		December 31,
		2014		2013
	Employees and related accruals	$	1,234	$	626
	Consultants and board of directors members		353		314
	Accrual for OCS royalties payment		289		120
	Accrued expenses		992		663
	Other		18		5
		$	2,886	$	1,728

RESEARCH_AND_DEVELOPMENT_FUNDI1

RESEARCH AND DEVELOPMENT FUNDING ARRANGEMENTS AND OTHERS (Tables)	12 Months Ended
	Dec. 31, 2014
RESEARCH AND DEVELOPMENT FUNDING ARRANGEMENT [Abstract]
Schedule of Balances Recorded		December 31,
		2014				2013
	Embedded Derivatives	$	-		$	12,431
	Research and Development Component		421			758
		$	421		$	13,189
Schedule of Fair Value Assumptions	In estimating the embedded derivatives' fair value, the Company used the following assumptions:
		August 20,				December 31,
		2014
						2013
		Amended Funding Arrangement
	Risk-free interest rate (1)		0.09	%			0.25	%
	Expected volatility (2)		57.76	%			55.65	%
	Expected life (in years) (3)		0.84				1.5
	Expected dividend yield (4)		0				0
	(1)  Risk-free interest rate – based on the yields from U.S. treasury bonds with equivalent terms.
	(2)  Expected volatility - was calculated based on actual historical share price movements of the Company over a term that is equivalent to the expected term of the embedded derivative.
	(3)  Expected life - the expected life of the conversion feature was based on the term of the embedded derivative.
	(4)  Expected dividend yield - was based on the fact that the Company has not paid dividends to ordinary shareholders in the past and does not expect to pay dividends to ordinary shareholders.

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES (Tables)	12 Months Ended
	Dec. 31, 2014
COMMITMENTS AND CONTINGENCIES [Abstract]
Future Rental Commitments Under Operating Leases	December 31,
	2015	$	908
	2016		592
	2017		561
	2018		269
		$	2,330

SHAREHOLDERS_EQUITY_Tables

SHAREHOLDERS' EQUITY (Tables)	12 Months Ended
	Dec. 31, 2014
Schedule of Share-based Compensation Arrangements by Grantee [Line Items]
Schedule Of weighted-average assumptions for general options granted	The Company used the following weighted-average assumptions for general options granted to non-employees:
		Year ended December 31,
		2014			2013			2012
	Volatility	64	%		67	%		75	%
	Risk-free interest rate	1.77	%		1.03	%		0.66	%
	Dividend yield	0	%		0	%		0	%
	Expected life (years)	5.7			4.5			4.3
Schedule of Stock-Based Compensation Expenses	The stock-based compensation expenses are included as follows in the expense categories:
		Year ended December 31,
		2014				2013				2012
	Cost of revenue	$	399			$	320			$	59
	Research and development expenses, net		1,862				1,724				1,239
	Marketing and business development expenses		162				151				192
	General and administrative expenses		1,210				1,348				979
		$	3,633			$	3,543			$	2,469
Employees and Directors [Member]
Schedule of Share-based Compensation Arrangements by Grantee [Line Items]
Schedule Of Option Activity	Transactions related to the grant of options to employees and directors under the above plans during the year ended December 31, 2014, were as follows:
			Number of			Weighted			Weighted			Aggregate
			options			average			average			intrinsic
						exercise			remaining contractual			value
						price			life
						$			Years			$
	Options outstanding at beginning of year		5,628,653			3.76			7.07			29,232
	Options granted		1,172,350			8.76						63
	Options exercised		(336,289	)		3.46						2,119
	Options expired		(756	)		3.43						4
	Options forfeited		(199,588	)		6.09						545
	Options outstanding at end of year		6,264,370			4.64			6.74			23,627
	Options vested and expected to vest at end of year		6,091,709			4.59			6.68			23,227
	Exercisable at end of year		3,243,863			3.19			5			16,668
Non Employees [Member]
Schedule of Share-based Compensation Arrangements by Grantee [Line Items]
Schedule Of Option Activity			Year ended December 31, 2014
			Number of options			Weighted			Weighted
						average			average
						exercise			remaining contractual
						price			life
						$			Years
	Options outstanding at beginning of year		416,500			5.23			3.6
	Options granted		113,000			8.47
	Options exercised		(53,000	)		4.9
	Options expired		(8,334	)		5.45
	Options forfeited		(1,666	)		5.45
	Options outstanding at end of year		466,500			5.71			3.75
	Options vested and expected to vest at end of year		466,500			5.71			3.75
	Exercisable at end of year		392,680			6.04			3.53

INCOME_TAXES_Tables

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2014
INCOME TAXES [Abstract]
Schedule Of Loss Before Taxes		Year ended December 31,
		2014			2013			2012
	Domestic (Israel)	$	11,138		$	13,859		$	13,370
	Foreign		(404	)		(276	)		258
		$	10,734		$	13,583		$	13,628
Summary Of Deferred Tax Assets And Liabilities		December 31,
			2014			2013
	Operating loss carryforward	$	49,238		$	52,092
	Research and development credit		4,018			3,265
	Accrued social benefits and other		1,183			182
	Property and equipment		(365	)		-
	Deferred tax asset before valuation allowance		54,074			55,539
	Valuation allowance		(54,074	)		(55,539	)
	Net deferred tax asset	$	-		$	-

FAIR_VALUE_MEASUREMENTS_Tables

FAIR VALUE MEASUREMENTS (Tables)	12 Months Ended
	Dec. 31, 2014
FAIR VALUE MEASUREMENTS [Abstract]
Schedule of financial assets and liabilities measured at fair value on a recurring basis		31-Dec-14
		Fair value measurements
	Description	Fair value			Level 1		Level 2		Level 3
	Investment in Evogene	$	1,054		$	1,054	$	-	$	-
	Foreign currency derivative contracts		141			-		141		-
	Total financial assets	$	1,195		$	1,054	$	141	$	-
		31-Dec-13
		Fair value measurements
	Description	Fair value			Level 1		Level 2		Level 3
	Investment in Evogene	$	4,565		$	4,565	$	-	$	-
	Embedded Derivatives		(12,431	)		-		-		(12,431	)
Schedule Of Changes In Level 3 Instruments Measured On A Recurring Basis Using Significant Unobservable Inputs			Fair value
			of embedded derivatives
	Balance at January 1, 2013 *)	$	6,864
	Fair value of Exchange Option within the proceeds under the mAb Funding Agreement		4,756
	Change in fair value of Exchange Option and embedded derivatives within research and development arrangement		811
	Balance at December 31, 2013 *)		12,431
	Change in fair value of Exchange Option and embedded derivatives within research and development arrangement		(269	)
	Issuance of shares in respect to Termination and Equity Conversion Agreement		(12,162	)
	Balance at December 31, 2014	$	-
Schedule of Fair Value of Outstanding Options to Non-employee			Fair value
			of outstanding options to non- employee
	Balance at January 1, 2013	$	264
	Change in fair value of liability with respect to outstanding options to non- employee		(104	)
	Classification of portion liability with respect to outstanding options to non-employee to additional paid in capital		(160	)
	Balance at December 31, 2013		-

GEOGRAPHIC_INFORMATION_AND_MAJ1

GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS (Tables)	12 Months Ended
	Dec. 31, 2014
GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS [Abstract]
Total Revenues And Long-Lived Assets By Geographic Area		Year ended December 31,
			2014			2013			2012
	Revenue from sales to customers:
	Israel	$	212		$	260		$	242
	Europe		12,155			3,289			-
	Total revenue	$	12,367		$	3,549		$	242
		December 31,
			2014			2013
	Long-lived assets:
	Israel	$	1,217		$	567
	United States		1,513			641
	Total long-lived assets	$	2,730		$	1,208
Sales To A Single Customer Exceeding 10%:		Year ended December 31,
			2014			2013			2012
	Sales to a single customer exceeding 10%:
	Customer A		98	%		93	%		100	%

FINANCIAL_INCOME_LOSS_NET_Tabl

FINANCIAL INCOME (LOSS), NET (Tables)	12 Months Ended
	Dec. 31, 2014
FINANCIAL INCOME (LOSS), NET [Abstract]
SCHEDULE OF FINANCIAL INCOME (LOSS), NET		Year ended December 31,
			2014			2013			2012
	Interest income	$	346		$	169		$	301
	Bank fees and other finance expenses		(16	)		(28	)		(61	)
	Change in fair value of research and development funding arrangement		269			(811	)		(588	)
	Change in fair value of liability with respect to outstanding options to non-employee		-			104			20
	Loss in respect to Termination and Equity Conversion Agreement		(792	)
	Gain from sales of marketable securities		2,345			3,711			-
	Foreign currency translation adjustments		(394	)		315			242
	Financial income (loss), net	$	1,758		$	3,460		$	(86	)

LOSSES_PER_SHARE_Tables

LOSSES PER SHARE (Tables)	12 Months Ended
	Dec. 31, 2014
LOSSES PER SHARE [Abstract]
Schedule of computation of basic and diluted losses per share		Year ended December 31,
			2014			2013			2012
	Numerator:
	Net loss for basic loss per share	$	(11,094	)	$	(14,083	)	$	(13,628	)
	Loss in respect to change in fair value of research and development funding arrangement		(1,295	)		-			(16	)
	Net loss for basic loss per share	$	(12,389	)	$	(14,083	)	$	(13,644	)
	Denominator:
	Weighted average number of ordinary shares used in computing basic net loss per share		47,808,855			38,869,438			35,844,496
	Dilutive average number of ordinary shares in respect to research and development funding arrangement		578,208			-			404,766
	Weighted average number of ordinary shares used in computing diluted net loss per share		48,387,063			38,869,438			36,249,262
	Diluted earnings per ordinary share	$	(0.26	)	$	(0.36	)	$	(0.38	)

GENERAL_Details

GENERAL (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013
Research and Development Collaboration and Licensing Agreement
Upfront payment received	$10,000
Potential milestone compensation	500,000
Preclinical milestone compensation	$30,000

SIGNIFICANT_ACCOUNTING_POLICIE3

SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)

12 Months Ended

12 Months Ended

In Thousands, except Share data, unless otherwise specified

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

USD ($)

USD ($)

USD ($)

Neviah [Member]

Neviah [Member]

Keddem [Member]

Options [Member]

Options [Member]

Options [Member]

Warrants [Member]

Warrants [Member]

Warrants [Member]

Exchange Option [Member]

item

USD ($)

Merck Holdings [Member]

Convertible Bridge Loan Agreement [Member]

EUR (€)

SIGNIFICANT ACCOUNTING POLICIES [Abstract]

Average interest rate, short-term bank deposits in U.S. dollars

0.85%

0.63%

Marketable securities impairment losses

$0

$0

$0

Evogene shares held

113,405

232,292

Average interest rate, long-term bank deposits in U.S. dollars

1.02%

Deferred revenue

1,789

6,711

Number of licensed programs to achieve substantive milestones revenues

1

Revenue recognition under milestone method

7,200

Severance expenses

344

294

252

Derivative, notional amount

5,626

Derivative, contract period

9 months

Derivative, maturity date

30-Sep-15

Unrealized gains arising from derivative contracts

141

Derivative related expenses

0

Fair value of outstanding forward contracts

141

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Number of shares

6,363,348

6,271,819

6,170,554

333,333

500,000

500,000

2,157,293

Schedule of Equity Method Investments [Line Items]

Number of investments in affiliates

2

Ownership percentage

25.12%

36.00%

Face amount

500

Loan grant date

17-Dec-14

Investment amount

155

Maturity term

18 months

Interest rate (as a percent)

2.00%

Equity losses

($155)

($155)

SIGNIFICANT_ACCOUNTING_POLICIE4

SIGNIFICANT ACCOUNTING POLICIES (Schedule of Depreciation Rates for Property and Equipment) (Details)	12 Months Ended
	Dec. 31, 2014
Computers, software and related equipment [Member]
Property, Plant and Equipment [Line Items]
Annual depreciation rate	33.00%
Laboratory equipment and office furniture [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Annual depreciation rate	6.00%
Laboratory equipment and office furniture [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Annual depreciation rate	20.00%
Laboratory equipment and office furniture [Member] | Mainly [Member]
Property, Plant and Equipment [Line Items]
Annual depreciation rate	20.00%
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Annual depreciation rate	Shorter of the term of the lease or useful life

SIGNIFICANT_ACCOUNTING_POLICIE5

SIGNIFICANT ACCOUNTING POLICIES (Schedule of Weighted-Average Assumptions for Granted Options) (Details) (Stock options [Member])	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Stock options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Volatility	56.00%	71.00%	82.00%
Risk-free interest rate	1.53%	1.25%	0.66%
Dividend yield	0.00%	0.00%	0.00%
Expected life (years)	4 years 8 months 12 days	4 years 4 months 24 days	4 years 6 months

CASH_AND_CASH_EQUIVALENTS_Deta

CASH AND CASH EQUIVALENTS (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2014	Dec. 31, 2012	Dec. 31, 2011
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents	$28,751	$25,643	$16,374	$5,846
Bank deposits in U.S. dollars [Member]
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents	24,731
Weighted average interest rate	0.22%
Bank deposits in NIS [Member]
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents	1,441
Weighted average interest rate	1.32%
Cash in banks [Member]
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents	$2,579	$25,643

OTHER_ACCOUNTS_RECEIVABLE_AND_2

OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES [Abstract]
Prepaid expenses	$501	$492
Government authorities	58	1,172
Accrued interest	143	57
Receivables from foreign currency derivative contracts	141
Other	15	10
Other accounts receivable and prepaid expenses	$858	$1,731

PROPERTY_AND_EQUIPMENT_NET_Det

PROPERTY AND EQUIPMENT, NET (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Property, Plant and Equipment [Line Items]
Cost	$12,206	$10,026
Accumulated depreciation	9,476	8,818
Depreciated cost	2,730	1,208
Depreciation	658	370	299
Computers, software and related equipment [Member]
Property, Plant and Equipment [Line Items]
Cost	5,429	5,139
Accumulated depreciation	5,100	4,978
Laboratory equipment and office furniture [Member]
Property, Plant and Equipment [Line Items]
Cost	6,038	4,219
Accumulated depreciation	3,770	3,281
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Cost	739	668
Accumulated depreciation	$606	$559

OTHER_ACCOUNTS_PAYABLE_AND_ACC2

OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES [Abstract]
Employees and related accruals	$1,234	$626
Consultants and board of directors members	353	314
Accrual for OCS royalties payment	289	120
Accrued expenses	992	663
Other	18	5
Other accounts payable and accrued expenses	$2,886	$1,728

RESEARCH_AND_DEVELOPMENT_FUNDI2

RESEARCH AND DEVELOPMENT FUNDING ARRANGEMENTS AND OTHERS (Schedule Of Balances Recorded) (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
RESEARCH AND DEVELOPMENT FUNDING ARRANGEMENT [Abstract]
Embedded Derivatives		$12,431
Research and Development Component	421	758
Research and development funding arrangement	$421	$13,189

RESEARCH_AND_DEVELOPMENT_FUNDI3

RESEARCH AND DEVELOPMENT FUNDING ARRANGEMENTS AND OTHERS (Narrative) (Details)	12 Months Ended					12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2014	Dec. 31, 2014	Dec. 31, 2014	Dec. 31, 2014	Dec. 31, 2014
	USD ($)	USD ($)	USD ($)	ILS	ILS	Original Pipeline Funding Agreement [Member]	Amended Pipeline Funding Agreement [Member]	Termination and Equity Conversion Agreement [Member]	Minimum [Member]	Maximum [Member]
						USD ($)	USD ($)	ILS	Amended Pipeline Funding Agreement [Member]	Amended Pipeline Funding Agreement [Member]
									USD ($)	USD ($)
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Consideration received in funding arrangement						$5,000
Funding receivable						8,000
Options issued to agent						100,000
Warrant and option issuance costs						80
Change in fair value of liability with respect to outstanding options to non-employee		104	20
Right to exchange the Amended Participation Rights for ordinary shares, calculation description							(i) $ 13,000 less 50% of any cash consideration paid to Baize as Amended Participation Rights, divided by (ii) the average closing price of the Companybs ordinary shares during the twenty (20) trading days prior to the Actual Exchange Date (the bExchange Priceb)
Participation Rights							10.00%	5.00%
Price at which investors can exchange rights							$7.50		$3	$12
Ordinary shares eligible for purchase with warrants							500,000
Exercise price of warrants							$6
Number of shares to be issued upon exchange of Participation Rights							500,000
Financial income (expenses) related to embedded derivative	269	-811	-588
Researhc and development component	421	758
Amortization research and development component	337	230	130
Issuance of shares in respect to Termination and Equity Conversion Agreement, shares								1,600,000
Ordinary shares, par value per share				0.01	0.01			0.01
Financial expenses as a result of 2014 Baize Agreement	$792
Agreement, start date						20-Sep-10	21-Apr-13	20-Aug-14
Agreement, termination date						21-Apr-13	20-Aug-14

RESEARCH_AND_DEVELOPMENT_FUNDI4

RESEARCH AND DEVELOPMENT FUNDING ARRANGEMENTS AND OTHERS (Schedule Of Assumptions For Monoclonal Antibody Product) (Details) (Funding Arrangement [Member])	0 Months Ended		12 Months Ended
	Aug. 20, 2014		Dec. 31, 2013
Funding Arrangement [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Risk-free interest rate	0.09%	[1]	0.25%	[1]
Expected volatility	57.76%	[2]	55.65%	[2]
Expected life	10 months 2 days	[3]	1 year 6 months	[3]
Expected dividend yield	0.00%	[4]	0.00%	[4]
[1]	Risk-free interest rate b based on the yields from U.S. treasury bonds with equivalent terms.
[2]	Expected volatility - was calculated based on actual historical share price movements of the Company over a term that is equivalent to the expected term of the embedded derivative.
[3]	Expected life - the expected life of the conversion feature was based on the term of the embedded derivative.
[4]	Expected dividend yield - was based on the fact that the Company has not paid dividends to ordinary shareholders in the past and does not expect to pay dividends to ordinary shareholders.

COMMITMENTS_AND_CONTINGENCIES_1

COMMITMENTS AND CONTINGENCIES (Details) (USD $)	12 Months Ended			76 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Mar. 31, 2012
COMMITMENTS AND CONTINGENCIES [Abstract]
Operating lease expenses	$791	$724	$633
Minimum future rental commitments
2015	908
2016	592
2017	561
2018	269
Total future rental commitments	2,330
Participation rights, cost of revenue	263	616
Advisor, marketing and business development expenses	209	267
OCS [Member]
Government and Other Grants [Line Items]
Maximum royalty repaid as percentage of grant received	100.00%
Royalty expense	433	126
Contingent royalty obligations	8,899
OCS [Member] | Minimum [Member]
Government and Other Grants [Line Items]
Royalty percentage based on future revenues	3.00%
OCS [Member] | Maximum [Member]
Government and Other Grants [Line Items]
Royalty percentage based on future revenues	5.00%
BIRD [Member]
Government and Other Grants [Line Items]
Grants received				500
May 2012 Agreement With Advisor [Member]
Government and Other Grants [Line Items]
Retainer fee	5
Agreement, start date	9-May-12
Agreement, termination date	27-Feb-14
May 2012 Agreement With Advisor [Member] | Minimum [Member]
Government and Other Grants [Line Items]
Participation Rights	4.00%
New Agreement With Advisor [Member]
Government and Other Grants [Line Items]
Issuance expense	725
Agreement, start date	27-Feb-14
New Agreement With Advisor [Member] | Maximum [Member]
Government and Other Grants [Line Items]
Participation Rights	1.00%
Office leases [Member] | Israel [Member]
Guarantor Obligations [Line Items]
Bank guarantees in favor of lessor, foreign currency derivative contracts and credit card security	543
Office leases [Member] | Unites States [Member]
Guarantor Obligations [Line Items]
Bank guarantees in favor of lessor, foreign currency derivative contracts and credit card security	$74

SHAREHOLDERS_EQUITY_Issuance_o

SHAREHOLDERS' EQUITY (Issuance of Shares) (Details) (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Ordinary shares, shares authorized	100,000,000	100,000,000
Amount raised, net of issuance expenses	$70,718	$19,704	$6,267
At The Market Offering Program [Member]
Ordinary shares, shares authorized	6,000,000
Maximum authorized proceeds from issuance of common stock	40,000
Issuance of shares, net, shares	363,090
Amount raised, net of issuance expenses	3,801
Agreement [Member]
Ordinary shares, shares authorized	6,000,000
Issuance of shares, net, shares	6,900,000
Ordinary shares issued, price	$10.50
Payment of underwriting discounts and commissions	5,533
Agreement term	30 days
Agreement, additional shares issuable	900,000
Grant date fair value	1,576
Amount raised, net of issuance expenses	$66,917

SHAREHOLDERS_EQUITY_Share_Opti

SHAREHOLDERS' EQUITY (Share Option Plans) (Narrative) (Details) (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average fair value of stock options granted	$4.17	$3.83	$2.70
Unrecognized share-based compensation expense	$7,083
Unrecognized compensation cost, recognition period	2 years 5 months 16 days
2000 and 2010 Share Option Plans [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Ordinary shares reserved for issuance	18,977,240
Ordinary shares available for issuance	3,925,677
Vesting period	4 years
Award expiration period	10 years

SHAREHOLDERS_EQUITY_Schedule_O

SHAREHOLDERS' EQUITY (Schedule Of Option Activity) (Details) (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Employees and Directors [Member]
Number of options
Options outstanding at beginning of year	5,628,653
Options granted	1,172,350
Options exercised	-336,289
Options expired	-756
Options forfeited	-199,588
Options outstanding at end of year	6,264,370	5,628,653
Options vested and expected to vest at end of year	6,091,709
Exercisable at end of year	3,243,863
Weighted average exercise price
Options outstanding at beginning of year	$3.76
Options granted	$8.76
Options exercised	$3.46
Options expired	$3.43
Options forfeited	$6.09
Options outstanding at end of year	$4.64	$3.76
Options vested and expected to vest at end of year	$4.59
Exercisable at end of year	$3.19
Weighted average remaining contractual life
Options outstanding	6 years 8 months 26 days	7 years 25 days
Options vested and expected to vest at end of year	6 years 8 months 5 days
Exercisable at end of year	5 years
Aggregate intrinsic value
Options outstanding at beginning of year	$29,232
Options granted	63
Options exercised	2,119
Options expired	4
Options forfeited	545
Options outstanding at end of year	23,627	29,232
Options vested and expected to vest at end of year	23,227
Exercisable at end of year	$16,668
Non-employees [Member]
Number of options
Options outstanding at beginning of year	416,500
Options granted	113,000
Options exercised	-53,000
Options expired	-8,334
Options forfeited	-1,666
Options outstanding at end of year	466,500	416,500
Options vested and expected to vest at end of year	466,500
Exercisable at end of year	392,680
Weighted average exercise price
Options outstanding at beginning of year	$5.23
Options granted	$8.47
Options exercised	$4.90
Options expired	$5.45
Options forfeited	$5.45
Options outstanding at end of year	$5.71	$5.23
Options vested and expected to vest at end of year	$5.71
Exercisable at end of year	$6.04
Weighted average remaining contractual life
Options outstanding	3 years 9 months	3 years 7 months 6 days
Options vested and expected to vest at end of year	3 years 9 months
Exercisable at end of year	3 years 6 months 11 days

SHAREHOLDERS_EQUITY_Schedule_O1

SHAREHOLDERS' EQUITY (Schedule Of Weighted Average Assumptions) (Details) (Non-employees [Member])	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Non-employees [Member]
Schedule of Share-based Compensation Arrangements by Grantee [Line Items]
Volatility	64.00%	67.00%	75.00%
Risk-free interest rate	1.77%	1.03%	0.66%
Dividend yield	0.00%	0.00%	0.00%
Expected term	5 years 8 months 12 days	4 years 6 months	4 years 3 months 18 days

SHAREHOLDERS_EQUITY_Schedule_O2

SHAREHOLDERS' EQUITY (Schedule Of Stock Compensation Expense) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expenses	$3,633	$3,543	$2,469
Cost of sales [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expenses	399	320	59
Research and development expenses, net [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expenses	1,862	1,724	1,239
Marketing and business development expenses [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expenses	162	151	192
General and administrative expenses [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expenses	$1,210	$1,348	$979

SHAREHOLDERS_EQUITY_Board_Memb

SHAREHOLDERS' EQUITY (Board Members And Officers) (Narrative) (Details) (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Schedule of Share-based Compensation Arrangements by Grantee [Line Items]
Stock-based compensation expenses	$3,633	$3,543	$2,469
Chairman [Member]
Schedule of Share-based Compensation Arrangements by Grantee [Line Items]
Options granted	50,000	60,000
Stock options granted, exercise price	$10.07	$5.45
Vesting period	12 months	12 months
Risk-free interest rate		2.96%
Dividend yield		0.00%
Volatility		70.00%
Post-vesting termination rate		0.51%
Stock-based compensation expenses	348	108
Chairman [Member] | Minimum [Member]
Schedule of Share-based Compensation Arrangements by Grantee [Line Items]
Suboptimal exercise factor		1.00%
Expected term		3 years 9 months 11 days
Chairman [Member] | Maximum [Member]
Schedule of Share-based Compensation Arrangements by Grantee [Line Items]
Suboptimal exercise factor		2.11%
Expected term		5 years 5 months 16 days
CEO [Member]
Schedule of Share-based Compensation Arrangements by Grantee [Line Items]
Options granted	100,000	120,000
Stock options granted, exercise price	$10.07	$5.45
Vesting period	12 months	12 months
Risk-free interest rate		2.96%
Dividend yield		0.00%
Volatility		70.00%
Post-vesting termination rate		0.51%
Stock-based compensation expenses	$348	$108
CEO [Member] | Minimum [Member]
Schedule of Share-based Compensation Arrangements by Grantee [Line Items]
Suboptimal exercise factor		1.00%
Expected term		3 years 9 months 11 days
CEO [Member] | Maximum [Member]
Schedule of Share-based Compensation Arrangements by Grantee [Line Items]
Suboptimal exercise factor		2.11%
Expected term		5 years 5 months 16 days

INCOME_TAXES_Narrative_Details

INCOME TAXES (Narrative) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
INCOME TAXES [Abstract]
Israeli corporate tax rate	26.50%	25.00%	25.00%
Tax payment withheld	$360
U.S. income state and local taxes rate (as a percent)	35.00%
Milestone payments received	7,200
Israel [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carryforward	167,255
United States [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carryforward	$14,455
United States [Member] | Minimum [Member]
Operating Loss Carryforwards [Line Items]
Year of expiration of operating loss carryforward	31-Dec-19
United States [Member] | Maximum [Member]
Operating Loss Carryforwards [Line Items]
Year of expiration of operating loss carryforward	31-Dec-32

INCOME_TAXES_Encouragement_Of_

INCOME TAXES (Encouragement Of Capital Investments) (Narrative) (Details)	12 Months Ended
	Dec. 31, 2014
Encouragement Of Capital Investments Law [Line Items]
Tax exempt period	2 years
Reduced tax rate	20.00%
Term of investment	3 years
Period since approval was granted	14 years
Period since enterprise began operating	12 years
Period since year of election	12 years
Minimum [Member]
Encouragement Of Capital Investments Law [Line Items]
Reduced tax rate	10.00%
Maximum [Member]
Encouragement Of Capital Investments Law [Line Items]
Reduced tax rate	25.00%

INCOME_TAXES_Schedule_of_Loss_

INCOME TAXES (Schedule of Loss before Taxes) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
INCOME TAXES [Abstract]
Domestic (Israel)	$11,138	$13,859	$13,370
Foreign	-404	-276	258
Loss (income) before taxes	$10,734	$13,583	$13,628

INCOME_TAXES_Schedule_of_Defer

INCOME TAXES (Schedule of Deferred Tax Assets and Liabilities) (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
INCOME TAXES [Abstract]
Operating loss carryforward	$49,238	$52,092
Research and development credit	4,018	3,265
Accrued social benefits	1,183	182
Property and equipment	-365
Net deferred tax asset before valuation allowance	54,074	55,539
Valuation allowance	-54,074	-55,539
Net deferred tax asset

FAIR_VALUE_MEASUREMENTS_Schedu

FAIR VALUE MEASUREMENTS (Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis) (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment in Evogene	$1,054	$4,565
Foreign currency derivative contracts	141
Embedded Derivatives		-12,431
Total financial assets	1,195
Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment in Evogene	1,054	4,565
Foreign currency derivative contracts
Embedded Derivatives
Total financial assets	1,054
Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment in Evogene
Foreign currency derivative contracts	141
Embedded Derivatives
Total financial assets	141
Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment in Evogene
Foreign currency derivative contracts
Embedded Derivatives		-12,431
Total financial assets

FAIR_VALUE_MEASUREMENTS_Schedu1

FAIR VALUE MEASUREMENTS (Schedule Of Changes In Level 3 Instruments Measured On A Recurring Basis Using Significant Unobservable Inputs) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
FAIR VALUE MEASUREMENTS [Abstract]
Balance at beginning of year	$12,431	$6,864
Fair value of Exchange Option within the proceeds under the mAb Funding Agreement		4,756
Change in fair value of Exchange Option and embedded derivatives within research and development arrangement	-269	811
Issuance of shares in respect to Termination and Equity Conversion Agreement	-12,162
Balance at end of year		12,431
Researhc and development component	$421	$758

FAIR_VALUE_MEASUREMENTS_Schedu2

FAIR VALUE MEASUREMENTS (Schedule of Fair Value of Outstanding Options to Non-employee) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013
FAIR VALUE MEASUREMENTS [Abstract]
Beginning balance	$264
Change in fair value of liability with respect to outstanding options to non- employee	-104
Classification of portion liability with respect to outstanding options to non-employee to additional paid in capital	-160
Ending balance

GEOGRAPHIC_INFORMATION_AND_MAJ2

GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Segment Reporting Geograhic Area [Line Items]
Number of operating segments	1
Revenues	$12,367	$3,549	$242
Long-lived assets	2,730	1,208
Customer A [Member]
Segment Reporting Geograhic Area [Line Items]
Sales to a single customer exceeding 10%	98.00%	93.00%	100.00%
Unites States [Member]
Segment Reporting Geograhic Area [Line Items]
Long-lived assets	1,513	641
Europe [Member]
Segment Reporting Geograhic Area [Line Items]
Revenues	12,155	3,289
Israel [Member]
Segment Reporting Geograhic Area [Line Items]
Revenues	212	260	242
Long-lived assets	$1,217	$567

FINANCIAL_INCOME_LOSS_NET_Sche

FINANCIAL INCOME (LOSS), NET (Schedule of Financial Income (Loss), Net) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
FINANCIAL INCOME (LOSS), NET [Abstract]
Interest income	$346	$169	$301
Bank fees and other finance expenses	-16	-28	-61
Change in fair value of research and development funding arrangement	269	-811	-588
Change in fair value of liability with respect to outstanding options to non-employee		104	20
Loss in respect to Termination and Equity Conversion Agreement	-792
Gain from sales of marketable securities	2,345	3,711
Foreign currency translation adjustments	-394	315	242
Financial income (loss), net	$1,758	$3,460	($86)

RELATED_PARTY_BALANCES_AND_TRA1

RELATED PARTY BALANCES AND TRANSACTIONS (Narrative) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
RELATED PARTY BALANCES AND TRANSACTIONS [Abstract]
Related party transactions, revenue from the agreement with Neviah	$212	$260	$242

LOSSES_PER_SHARE_Schedule_of_C

LOSSES PER SHARE (Schedule of Computation of Basic and Diluted Losses Per Share)(Details) (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Numerator:
Net loss for basic loss per share	($11,094)	($14,083)	($13,628)
Loss in respect to change in fair value of research and development funding arrangement	-1,295		-16
Net loss for basic loss per share	($12,389)	($14,083)	($13,644)
Denominator:
Weighted average number of ordinary shares used in computing basic net loss per share	47,808,855	38,869,438	35,844,496
Dilutive average number of ordinary shares in respect to research and development funding arrangement	578,208		404,766
Weighted average number of ordinary shares used in computing diluted net loss per share	48,387,063	38,869,438	36,249,262
Diluted earnings per ordinary share	($0.26)	($0.36)	($0.38)